JP7290332B2 - 免疫療法のための化合物及び組成物 - Google Patents
免疫療法のための化合物及び組成物 Download PDFInfo
- Publication number
- JP7290332B2 JP7290332B2 JP2020048941A JP2020048941A JP7290332B2 JP 7290332 B2 JP7290332 B2 JP 7290332B2 JP 2020048941 A JP2020048941 A JP 2020048941A JP 2020048941 A JP2020048941 A JP 2020048941A JP 7290332 B2 JP7290332 B2 JP 7290332B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cells
- antibody
- cancer
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims description 154
- 239000000203 mixture Substances 0.000 title claims description 45
- 238000009169 immunotherapy Methods 0.000 title description 3
- 239000003814 drug Substances 0.000 claims description 94
- 230000008685 targeting Effects 0.000 claims description 90
- 239000001257 hydrogen Substances 0.000 claims description 72
- 229910052739 hydrogen Inorganic materials 0.000 claims description 72
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 72
- 229960000575 trastuzumab Drugs 0.000 claims description 58
- 238000011282 treatment Methods 0.000 claims description 44
- 230000003213 activating effect Effects 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 39
- 229940124597 therapeutic agent Drugs 0.000 claims description 28
- 229960005395 cetuximab Drugs 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 101150029707 ERBB2 gene Proteins 0.000 claims description 20
- 108060003951 Immunoglobulin Proteins 0.000 claims description 19
- 102000018358 immunoglobulin Human genes 0.000 claims description 19
- 239000012453 solvate Substances 0.000 claims description 17
- 206010006187 Breast cancer Diseases 0.000 claims description 16
- 208000026310 Breast neoplasm Diseases 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 239000002246 antineoplastic agent Substances 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 14
- 230000006907 apoptotic process Effects 0.000 claims description 10
- 229960001972 panitumumab Drugs 0.000 claims description 9
- 230000004663 cell proliferation Effects 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 229940022353 herceptin Drugs 0.000 claims description 8
- 229960002087 pertuzumab Drugs 0.000 claims description 8
- 229940082789 erbitux Drugs 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 101710183280 Topoisomerase Proteins 0.000 claims description 4
- 229940100198 alkylating agent Drugs 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 4
- 230000002280 anti-androgenic effect Effects 0.000 claims description 4
- 230000000340 anti-metabolite Effects 0.000 claims description 4
- 239000000051 antiandrogen Substances 0.000 claims description 4
- 229940100197 antimetabolite Drugs 0.000 claims description 4
- 239000002256 antimetabolite Substances 0.000 claims description 4
- 101150108262 gnrh1 gene Proteins 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 231100000782 microtubule inhibitor Toxicity 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 claims description 3
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 180
- -1 --NH 2 Chemical group 0.000 description 175
- 210000004027 cell Anatomy 0.000 description 158
- 125000000217 alkyl group Chemical group 0.000 description 125
- 125000005647 linker group Chemical group 0.000 description 97
- 125000003118 aryl group Chemical group 0.000 description 83
- 125000003342 alkenyl group Chemical group 0.000 description 80
- 102000039446 nucleic acids Human genes 0.000 description 76
- 108020004707 nucleic acids Proteins 0.000 description 76
- 150000007523 nucleic acids Chemical class 0.000 description 76
- 125000001072 heteroaryl group Chemical group 0.000 description 75
- 201000011510 cancer Diseases 0.000 description 72
- 241000282414 Homo sapiens Species 0.000 description 70
- 125000003545 alkoxy group Chemical group 0.000 description 65
- 108091007433 antigens Proteins 0.000 description 64
- 102000036639 antigens Human genes 0.000 description 64
- 239000000427 antigen Substances 0.000 description 63
- 229940079593 drug Drugs 0.000 description 63
- 238000000034 method Methods 0.000 description 60
- 230000027455 binding Effects 0.000 description 56
- 239000002245 particle Substances 0.000 description 56
- 125000000623 heterocyclic group Chemical group 0.000 description 52
- 210000004881 tumor cell Anatomy 0.000 description 50
- 125000001188 haloalkyl group Chemical group 0.000 description 48
- 125000001424 substituent group Chemical group 0.000 description 45
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 42
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 42
- 210000004443 dendritic cell Anatomy 0.000 description 41
- 229910052736 halogen Inorganic materials 0.000 description 41
- 150000002367 halogens Chemical class 0.000 description 38
- 125000000304 alkynyl group Chemical group 0.000 description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 37
- 201000010099 disease Diseases 0.000 description 32
- 239000003795 chemical substances by application Substances 0.000 description 31
- 239000000562 conjugate Substances 0.000 description 31
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 29
- 210000001519 tissue Anatomy 0.000 description 28
- 230000000694 effects Effects 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 26
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 235000018102 proteins Nutrition 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 125000000753 cycloalkyl group Chemical group 0.000 description 22
- 102000005962 receptors Human genes 0.000 description 21
- 108020003175 receptors Proteins 0.000 description 21
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 20
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 20
- 239000003446 ligand Substances 0.000 description 20
- 102000004196 processed proteins & peptides Human genes 0.000 description 20
- 125000006850 spacer group Chemical group 0.000 description 20
- 230000001225 therapeutic effect Effects 0.000 description 19
- 108010043610 KIR Receptors Proteins 0.000 description 17
- 102000002698 KIR Receptors Human genes 0.000 description 17
- 239000002105 nanoparticle Substances 0.000 description 17
- 210000000822 natural killer cell Anatomy 0.000 description 17
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 125000003396 thiol group Chemical class [H]S* 0.000 description 17
- 108091023037 Aptamer Proteins 0.000 description 16
- 230000003834 intracellular effect Effects 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 108091005804 Peptidases Proteins 0.000 description 15
- 102000035195 Peptidases Human genes 0.000 description 15
- 239000010410 layer Substances 0.000 description 15
- 229920000642 polymer Polymers 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- 210000003719 b-lymphocyte Anatomy 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 239000004365 Protease Substances 0.000 description 13
- 102000002689 Toll-like receptor Human genes 0.000 description 13
- 108020000411 Toll-like receptor Proteins 0.000 description 13
- 201000005202 lung cancer Diseases 0.000 description 13
- 208000020816 lung neoplasm Diseases 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 12
- 108060006698 EGF receptor Proteins 0.000 description 12
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 12
- 206010025323 Lymphomas Diseases 0.000 description 12
- 206010027476 Metastases Diseases 0.000 description 12
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 125000005842 heteroatom Chemical group 0.000 description 12
- 108010044426 integrins Proteins 0.000 description 12
- 102000006495 integrins Human genes 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 229910052717 sulfur Inorganic materials 0.000 description 12
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 11
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 150000001720 carbohydrates Chemical class 0.000 description 11
- 125000004093 cyano group Chemical group *C#N 0.000 description 11
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 125000003835 nucleoside group Chemical group 0.000 description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
- 229920001223 polyethylene glycol Polymers 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 10
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 235000014633 carbohydrates Nutrition 0.000 description 10
- 125000005843 halogen group Chemical group 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 229960004641 rituximab Drugs 0.000 description 10
- 239000003053 toxin Substances 0.000 description 10
- 231100000765 toxin Toxicity 0.000 description 10
- 108700012359 toxins Proteins 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 108700012439 CA9 Proteins 0.000 description 9
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 9
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 9
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 9
- 102000001301 EGF receptor Human genes 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 9
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 9
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 9
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 9
- 125000003282 alkyl amino group Chemical group 0.000 description 9
- 229940049595 antibody-drug conjugate Drugs 0.000 description 9
- 208000032839 leukemia Diseases 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 230000009401 metastasis Effects 0.000 description 9
- 239000002777 nucleoside Substances 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 8
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 8
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 230000021615 conjugation Effects 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 125000004663 dialkyl amino group Chemical group 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 125000004404 heteroalkyl group Chemical group 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 201000001441 melanoma Diseases 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 229950010550 resiquimod Drugs 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 230000009870 specific binding Effects 0.000 description 8
- 125000004434 sulfur atom Chemical group 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 7
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 7
- 206010061968 Gastric neoplasm Diseases 0.000 description 7
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 7
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 7
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 7
- 229930126263 Maytansine Natural products 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 7
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 7
- 125000004414 alkyl thio group Chemical group 0.000 description 7
- 125000002947 alkylene group Chemical group 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000000611 antibody drug conjugate Substances 0.000 description 7
- 125000004104 aryloxy group Chemical group 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 7
- 229960005277 gemcitabine Drugs 0.000 description 7
- 230000002147 killing effect Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 7
- 229960002450 ofatumumab Drugs 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 229960001612 trastuzumab emtansine Drugs 0.000 description 7
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 6
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 6
- 101150013553 CD40 gene Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 108010069236 Goserelin Proteins 0.000 description 6
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 6
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 6
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 6
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 6
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 6
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 6
- 102100022297 Integrin alpha-X Human genes 0.000 description 6
- 102000013462 Interleukin-12 Human genes 0.000 description 6
- 108010065805 Interleukin-12 Proteins 0.000 description 6
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 6
- 102000017578 LAG3 Human genes 0.000 description 6
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 6
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 6
- 206010060862 Prostate cancer Diseases 0.000 description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 6
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 6
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 6
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 125000005110 aryl thio group Chemical group 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 210000000182 cd11c+cd123- dc Anatomy 0.000 description 6
- 230000022534 cell killing Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 229940127089 cytotoxic agent Drugs 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
- 229960004679 doxorubicin Drugs 0.000 description 6
- 108020005243 folate receptor Proteins 0.000 description 6
- 102000006815 folate receptor Human genes 0.000 description 6
- 235000019152 folic acid Nutrition 0.000 description 6
- 239000011724 folic acid Substances 0.000 description 6
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 235000018977 lysine Nutrition 0.000 description 6
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical group C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 6
- 238000007363 ring formation reaction Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
- 102100034608 Angiopoietin-2 Human genes 0.000 description 5
- 108010048036 Angiopoietin-2 Proteins 0.000 description 5
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 5
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 5
- 102100027207 CD27 antigen Human genes 0.000 description 5
- 102100038078 CD276 antigen Human genes 0.000 description 5
- 102100032912 CD44 antigen Human genes 0.000 description 5
- 108010065524 CD52 Antigen Proteins 0.000 description 5
- 102100025221 CD70 antigen Human genes 0.000 description 5
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 5
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 5
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 5
- 108010055196 EphA2 Receptor Proteins 0.000 description 5
- 108010055191 EphA3 Receptor Proteins 0.000 description 5
- 108010055334 EphB2 Receptor Proteins 0.000 description 5
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 5
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 5
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 5
- 102100032031 Epidermal growth factor-like protein 7 Human genes 0.000 description 5
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 5
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 5
- 108010067306 Fibronectins Proteins 0.000 description 5
- 102000016359 Fibronectins Human genes 0.000 description 5
- 101710088083 Glomulin Proteins 0.000 description 5
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 5
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 5
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 5
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 5
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 5
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 5
- 101000921195 Homo sapiens Epidermal growth factor-like protein 7 Proteins 0.000 description 5
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 5
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 5
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 5
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 5
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 5
- 101100407307 Homo sapiens PDCD1LG2 gene Proteins 0.000 description 5
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 description 5
- 102100034980 ICOS ligand Human genes 0.000 description 5
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 5
- 108010047761 Interferon-alpha Proteins 0.000 description 5
- 102000006992 Interferon-alpha Human genes 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 5
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 5
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 5
- 238000011794 NU/NU nude mouse Methods 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 229930012538 Paclitaxel Natural products 0.000 description 5
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 5
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 206010038389 Renal cancer Diseases 0.000 description 5
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 5
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 5
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000000032 diagnostic agent Substances 0.000 description 5
- 229940039227 diagnostic agent Drugs 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 229960003668 docetaxel Drugs 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 229960000304 folic acid Drugs 0.000 description 5
- PFJKOHUKELZMLE-VEUXDRLPSA-N ganglioside GM3 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 PFJKOHUKELZMLE-VEUXDRLPSA-N 0.000 description 5
- 239000003862 glucocorticoid Substances 0.000 description 5
- 125000004474 heteroalkylene group Chemical group 0.000 description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 201000010982 kidney cancer Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 108010093470 monomethyl auristatin E Proteins 0.000 description 5
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 229960001603 tamoxifen Drugs 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 239000000439 tumor marker Substances 0.000 description 5
- HOFQVRTUGATRFI-XQKSVPLYSA-N vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 5
- 229960003048 vinblastine Drugs 0.000 description 5
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 4
- 238000011729 BALB/c nude mouse Methods 0.000 description 4
- 102100039496 Choline transporter-like protein 4 Human genes 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 108010016626 Dipeptides Proteins 0.000 description 4
- 229920001917 Ficoll Polymers 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 4
- 108010052199 HLA-C Antigens Proteins 0.000 description 4
- 102000006354 HLA-DR Antigens Human genes 0.000 description 4
- 108010058597 HLA-DR Antigens Proteins 0.000 description 4
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 4
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 4
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 4
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 4
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 4
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 4
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 4
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 description 4
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 4
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 4
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 4
- 101150030213 Lag3 gene Proteins 0.000 description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 4
- 102000003735 Mesothelin Human genes 0.000 description 4
- 108090000015 Mesothelin Proteins 0.000 description 4
- 102000029749 Microtubule Human genes 0.000 description 4
- 108091022875 Microtubule Proteins 0.000 description 4
- 102100034256 Mucin-1 Human genes 0.000 description 4
- 102100023123 Mucin-16 Human genes 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 101710043865 Nectin-4 Proteins 0.000 description 4
- 102100035486 Nectin-4 Human genes 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- 102000005650 Notch Receptors Human genes 0.000 description 4
- 108010070047 Notch Receptors Proteins 0.000 description 4
- 108010042215 OX40 Ligand Proteins 0.000 description 4
- 102000004473 OX40 Ligand Human genes 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 4
- 102000014128 RANK Ligand Human genes 0.000 description 4
- 108010025832 RANK Ligand Proteins 0.000 description 4
- 108091007561 SLC44A4 Proteins 0.000 description 4
- 102000003705 Syndecan-1 Human genes 0.000 description 4
- 108090000058 Syndecan-1 Proteins 0.000 description 4
- 102000007000 Tenascin Human genes 0.000 description 4
- 108010008125 Tenascin Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 4
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 4
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 4
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 description 4
- 108091008605 VEGF receptors Proteins 0.000 description 4
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 4
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 4
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 229940022836 benlysta Drugs 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 210000003679 cervix uteri Anatomy 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 229960000975 daunorubicin Drugs 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- 229960000255 exemestane Drugs 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 229960002949 fluorouracil Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 201000009277 hairy cell leukemia Diseases 0.000 description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 229960000908 idarubicin Drugs 0.000 description 4
- 229960002751 imiquimod Drugs 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- 210000004688 microtubule Anatomy 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 4
- 229920000570 polyether Polymers 0.000 description 4
- 125000006684 polyhaloalkyl group Polymers 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 150000004804 polysaccharides Chemical class 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 101150047061 tag-72 gene Proteins 0.000 description 4
- 229960001278 teniposide Drugs 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- FKBHRUQOROFRGD-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2[C]3C=CC=CC3=NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC FKBHRUQOROFRGD-IELIFDKJSA-N 0.000 description 4
- 229960002066 vinorelbine Drugs 0.000 description 4
- 229940055760 yervoy Drugs 0.000 description 4
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 3
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- 206010014733 Endometrial cancer Diseases 0.000 description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 101100341519 Homo sapiens ITGAX gene Proteins 0.000 description 3
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 3
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 3
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 3
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001082241 Lythrum hyssopifolia Species 0.000 description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 3
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 3
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 3
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 208000006994 Precancerous Conditions Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
- 229940124614 TLR 8 agonist Drugs 0.000 description 3
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 230000033289 adaptive immune response Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 229960002932 anastrozole Drugs 0.000 description 3
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 238000009175 antibody therapy Methods 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 150000001540 azides Chemical class 0.000 description 3
- 229960003270 belimumab Drugs 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 229960003008 blinatumomab Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910021538 borax Inorganic materials 0.000 description 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 3
- 229940127093 camptothecin Drugs 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 201000007455 central nervous system cancer Diseases 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 229960000684 cytarabine Drugs 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 229950007409 dacetuzumab Drugs 0.000 description 3
- 229960000640 dactinomycin Drugs 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229960001904 epirubicin Drugs 0.000 description 3
- 229930013356 epothilone Natural products 0.000 description 3
- 150000003883 epothilone derivatives Chemical class 0.000 description 3
- 229960005420 etoposide Drugs 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 150000002270 gangliosides Chemical class 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 229960002913 goserelin Drugs 0.000 description 3
- 150000007857 hydrazones Chemical class 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 108091008042 inhibitory receptors Proteins 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229960005386 ipilimumab Drugs 0.000 description 3
- 150000002540 isothiocyanates Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 229960003881 letrozole Drugs 0.000 description 3
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
- 229960004844 lovastatin Drugs 0.000 description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000000873 masking effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 229960001156 mitoxantrone Drugs 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000006682 monohaloalkyl group Chemical group 0.000 description 3
- 108010059074 monomethylauristatin F Proteins 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 3
- YZOQZEXYFLXNKA-UHFFFAOYSA-N n-[4-(4-amino-2-ethylimidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide Chemical compound C1=CC=CC2=C(N(C(CC)=N3)CCCCNS(C)(=O)=O)C3=C(N)N=C21 YZOQZEXYFLXNKA-UHFFFAOYSA-N 0.000 description 3
- 229960003301 nivolumab Drugs 0.000 description 3
- 229950006344 nocodazole Drugs 0.000 description 3
- 210000004882 non-tumor cell Anatomy 0.000 description 3
- 230000000683 nonmetastatic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000001301 oxygen Chemical group 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 229960002621 pembrolizumab Drugs 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 3
- 229960004622 raloxifene Drugs 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000010339 sodium tetraborate Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 229950007217 tremelimumab Drugs 0.000 description 3
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 3
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 3
- 229950005972 urelumab Drugs 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 description 2
- GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 2
- MKSPBYRGLCNGRC-OEMOKZHXSA-N (2s)-2-[[(2s)-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s,3r)-2-[[(2s)-2-aminopropanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound O=C([C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(=O)[C@H](C)N)[C@@H](C)O)CC(C)C)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MKSPBYRGLCNGRC-OEMOKZHXSA-N 0.000 description 2
- HIKCELHIZSKMGI-LJAQVGFWSA-N (2s)-3-[[4-[[1h-benzimidazol-2-ylmethyl(cyclohexylcarbamoyl)amino]methyl]benzoyl]amino]-2-(phenylmethoxycarbonylamino)propanoic acid Chemical group C([C@@H](C(=O)O)NC(=O)OCC=1C=CC=CC=1)NC(=O)C(C=C1)=CC=C1CN(CC=1NC2=CC=CC=C2N=1)C(=O)NC1CCCCC1 HIKCELHIZSKMGI-LJAQVGFWSA-N 0.000 description 2
- ZBVJFYPGLGEMIN-OYLNGHKZSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-( Chemical group C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1.C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 ZBVJFYPGLGEMIN-OYLNGHKZSA-N 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 2
- SWXOGPJRIDTIRL-DOUNNPEJSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s)-1-amino-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-DOUNNPEJSA-N 0.000 description 2
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 2
- WTJXVDPDEQKTCV-VQAITOIOSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O WTJXVDPDEQKTCV-VQAITOIOSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- SVBZCXQPNPURIX-UHFFFAOYSA-N 1-(2-amino-2-methylpropyl)-2-(ethoxymethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)N)C3=C(N)N=C21 SVBZCXQPNPURIX-UHFFFAOYSA-N 0.000 description 2
- FNGOMDSFESDBEW-UHFFFAOYSA-N 1-(4-amino-2-ethyl-7-pyridin-4-ylimidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol Chemical compound C1=CC2=C3N(CC(C)(C)O)C(CC)=NC3=C(N)N=C2C=C1C1=CC=NC=C1 FNGOMDSFESDBEW-UHFFFAOYSA-N 0.000 description 2
- PISWNSOQFZRVJK-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 PISWNSOQFZRVJK-XLPZGREQSA-N 0.000 description 2
- BIWKOBSVKIEQLD-UHFFFAOYSA-N 1-[1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-yl]-3-cyclopentylurea Chemical compound NC1=NC=2C=CC=CC2C2=C1N=C(N2CC(C)(C)NC(=O)NC2CCCC2)COCC BIWKOBSVKIEQLD-UHFFFAOYSA-N 0.000 description 2
- QNOAFXQYZVGWMO-UHFFFAOYSA-N 1-[1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-yl]-3-propylurea Chemical compound NC1=NC=2C=CC=CC2C2=C1N=C(N2CC(C)(C)NC(=O)NCCC)COCC QNOAFXQYZVGWMO-UHFFFAOYSA-N 0.000 description 2
- ZLZKHTRPQRBTHF-UHFFFAOYSA-N 1-[2-[2-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-3-phenylurea Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCCNC(=O)NC1=CC=CC=C1 ZLZKHTRPQRBTHF-UHFFFAOYSA-N 0.000 description 2
- RABCHZGIHKCQEP-UHFFFAOYSA-N 1-[2-[2-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-3-cyclohexylurea Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCCNC(=O)NC1CCCCC1 RABCHZGIHKCQEP-UHFFFAOYSA-N 0.000 description 2
- RLGNIXAVMDVPSM-UHFFFAOYSA-N 1-[4-(3,5-dichlorophenyl)sulfonylbutyl]-2-ethylimidazo[4,5-c]quinolin-4-amine Chemical compound CCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCCS(=O)(=O)C1=CC(Cl)=CC(Cl)=C1 RLGNIXAVMDVPSM-UHFFFAOYSA-N 0.000 description 2
- GTUCHIHDDSGYMP-UHFFFAOYSA-N 1-[4-amino-2-(ethoxymethyl)-7-pyridin-3-ylimidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical compound C1=CC2=C3N(CC(C)(C)O)C(COCC)=NC3=C(N)N=C2C=C1C1=CC=CN=C1 GTUCHIHDDSGYMP-UHFFFAOYSA-N 0.000 description 2
- QHPGZBNQBMJYAG-UHFFFAOYSA-N 1-[4-amino-2-(ethoxymethyl)-7-pyridin-4-ylimidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical compound C1=CC2=C3N(CC(C)(C)O)C(COCC)=NC3=C(N)N=C2C=C1C1=CC=NC=C1 QHPGZBNQBMJYAG-UHFFFAOYSA-N 0.000 description 2
- FHJATBIERQTCTN-UHFFFAOYSA-N 1-[4-amino-2-(ethylaminomethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical compound C1=CC=CC2=C(N(C(CNCC)=N3)CC(C)(C)O)C3=C(N)N=C21 FHJATBIERQTCTN-UHFFFAOYSA-N 0.000 description 2
- NXRIDAMREUIFDQ-UHFFFAOYSA-N 1-[4-amino-7-[5-(hydroxymethyl)pyridin-3-yl]-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical compound C1=CC2=C3N(CC(C)(C)O)C(CCOC)=NC3=C(N)N=C2C=C1C1=CN=CC(CO)=C1 NXRIDAMREUIFDQ-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- DITHACKITKTCMN-UHFFFAOYSA-N 2-(ethoxymethyl)-1-[2-(3-phenylmethoxypropoxy)ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCCCOCC1=CC=CC=C1 DITHACKITKTCMN-UHFFFAOYSA-N 0.000 description 2
- HLPUJJZDRNYGNZ-UHFFFAOYSA-N 2-(ethoxymethyl)-1-n-propan-2-yl-6,7,8,9-tetrahydroimidazo[4,5-c]quinoline-1,4-diamine Chemical compound C1CCCC2=C(N(C(COCC)=N3)NC(C)C)C3=C(N)N=C21 HLPUJJZDRNYGNZ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 2
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 2
- DXDGDCBZWVCDHG-UHFFFAOYSA-N 2-amino-n-[2-(4-amino-2-butylimidazo[4,5-c][1,5]naphthyridin-1-yl)ethyl]-4-methylpentanamide Chemical compound C1=CC=NC2=C(N(C(CCCC)=N3)CCNC(=O)C(N)CC(C)C)C3=C(N)N=C21 DXDGDCBZWVCDHG-UHFFFAOYSA-N 0.000 description 2
- RFZSZPJGVHUALX-UHFFFAOYSA-N 2-butyl-1-(3-methylsulfonylpropyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(CCCC)=N3)CCCS(C)(=O)=O)C3=C(N)N=C21 RFZSZPJGVHUALX-UHFFFAOYSA-N 0.000 description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 2
- NFYMGJSUKCDVJR-UHFFFAOYSA-N 2-propyl-[1,3]thiazolo[4,5-c]quinolin-4-amine Chemical group C1=CC=CC2=C(SC(CCC)=N3)C3=C(N)N=C21 NFYMGJSUKCDVJR-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- HCLMCYDABWTVKQ-UHFFFAOYSA-N 3-[4-amino-2-(ethoxymethyl)-7-pyridin-3-ylimidazo[4,5-c]quinolin-1-yl]propane-1,2-diol Chemical compound C1=CC2=C3N(CC(O)CO)C(COCC)=NC3=C(N)N=C2C=C1C1=CC=CN=C1 HCLMCYDABWTVKQ-UHFFFAOYSA-N 0.000 description 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- SKPRPEJLFKCOAB-UHFFFAOYSA-N 3-nitroquinolin-4-amine Chemical compound C1=CC=C2C(N)=C([N+]([O-])=O)C=NC2=C1 SKPRPEJLFKCOAB-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- WPCIWMJWVMQOBT-UHFFFAOYSA-N 4-[4-amino-2-(ethoxymethyl)-1-(2-hydroxy-2-methylpropyl)imidazo[4,5-c]quinolin-7-yl]-n-methoxy-n-methylbenzamide Chemical compound C1=CC2=C3N(CC(C)(C)O)C(COCC)=NC3=C(N)N=C2C=C1C1=CC=C(C(=O)N(C)OC)C=C1 WPCIWMJWVMQOBT-UHFFFAOYSA-N 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N 4-methyl-1h-indole Chemical compound CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 2
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical group [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 2
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 2
- CURQWZKBAVHJPH-UHFFFAOYSA-N 6-chloro-5-fluoro-3-methyl-1h-indole Chemical compound ClC1=C(F)C=C2C(C)=CNC2=C1 CURQWZKBAVHJPH-UHFFFAOYSA-N 0.000 description 2
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 102100038778 Amphiregulin Human genes 0.000 description 2
- 108010033760 Amphiregulin Proteins 0.000 description 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 101800001382 Betacellulin Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 description 2
- 108010051834 CTTHWGFTLC peptide Proteins 0.000 description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 102000004225 Cathepsin B Human genes 0.000 description 2
- 108090000712 Cathepsin B Proteins 0.000 description 2
- 108010084457 Cathepsins Proteins 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 108010016906 Epigen Proteins 0.000 description 2
- 102100030323 Epigen Human genes 0.000 description 2
- 101800000155 Epiregulin Proteins 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002306 Glycocalyx Polymers 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 description 2
- 101000945371 Homo sapiens Killer cell immunoglobulin-like receptor 2DL2 Proteins 0.000 description 2
- 101000945333 Homo sapiens Killer cell immunoglobulin-like receptor 2DL3 Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 description 2
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 108010014726 Interferon Type I Proteins 0.000 description 2
- 102000002227 Interferon Type I Human genes 0.000 description 2
- 108010065637 Interleukin-23 Proteins 0.000 description 2
- 102000013264 Interleukin-23 Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 description 2
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 description 2
- 102100033634 Killer cell immunoglobulin-like receptor 2DL3 Human genes 0.000 description 2
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- OLHLJBVALXTBSQ-UHFFFAOYSA-N Lupulone Natural products CC(C)CC(=O)C1C(=O)C(CC=C(C)C)C(=O)C(CC=C(C)C)(CC=C(C)C)C1=O OLHLJBVALXTBSQ-UHFFFAOYSA-N 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229940122255 Microtubule inhibitor Drugs 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 2
- 102000014413 Neuregulin Human genes 0.000 description 2
- 108050003475 Neuregulin Proteins 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 108010016076 Octreotide Proteins 0.000 description 2
- FADYJNXDPBKVCA-STQMWFEESA-N Phe-Lys Chemical group NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 FADYJNXDPBKVCA-STQMWFEESA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 2
- 102100029837 Probetacellulin Human genes 0.000 description 2
- 102100025498 Proepiregulin Human genes 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 description 2
- 108700012411 TNFSF10 Proteins 0.000 description 2
- 108010046722 Thrombospondin 1 Proteins 0.000 description 2
- 102100036034 Thrombospondin-1 Human genes 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 2
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- UDHPLJGOINSMFG-UHFFFAOYSA-N [4-[4-amino-1-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-2-(ethoxymethyl)imidazo[4,5-c]quinolin-7-yl]phenyl]methanol Chemical compound CCOCC1=NC2=C(N)N=C3C=C(C=4C=CC(CO)=CC=4)C=CC3=C2N1CC1COC(C)(C)O1 UDHPLJGOINSMFG-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 229940040563 agaric acid Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 108010044540 auristatin Proteins 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- WPVSVIXDXMNGGN-UHFFFAOYSA-N beta-bitter acid Natural products CC(C)CC(=O)C1=C(O)C(CC=C(C)C)(CC=C(C)C)C(=O)C(CC=C(C)C)=C1O WPVSVIXDXMNGGN-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229960000455 brentuximab vedotin Drugs 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 108700008462 cetrorelix Proteins 0.000 description 2
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 2
- 229960003230 cetrorelix Drugs 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000011247 coating layer Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 210000004544 dc2 Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000004982 dihaloalkyl group Chemical group 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000000375 direct analysis in real time Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000012063 dual-affinity re-targeting Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 108060002566 ephrin Proteins 0.000 description 2
- 102000012803 ephrin Human genes 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 208000010749 gastric carcinoma Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000004517 glycocalyx Anatomy 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 125000004470 heterocyclooxy group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 108010021336 lanreotide Proteins 0.000 description 2
- 229960002437 lanreotide Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- LSDULPZJLTZEFD-UHFFFAOYSA-N lupulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)C(CC=C(C)C)(CC=C(C)C)C1=O LSDULPZJLTZEFD-UHFFFAOYSA-N 0.000 description 2
- 210000005210 lymphoid organ Anatomy 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229940110254 minocin Drugs 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- OOHUVTQQUWSOPZ-UHFFFAOYSA-N n-[1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-yl]-2-ethoxyacetamide Chemical compound C1=CC=CC2=C3N(CC(C)(C)NC(=O)COCC)C(COCC)=NC3=C(N)N=C21 OOHUVTQQUWSOPZ-UHFFFAOYSA-N 0.000 description 2
- BQLBSBWCGKYXGM-UHFFFAOYSA-N n-[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)-2,2-dimethylpropyl]benzamide Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC(C)(C)CNC(=O)C1=CC=CC=C1 BQLBSBWCGKYXGM-UHFFFAOYSA-N 0.000 description 2
- SBHDTQQLGBQXLR-UHFFFAOYSA-N n-[3-[4-amino-1-(2-hydroxy-2-methylpropyl)-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-7-yl]phenyl]methanesulfonamide Chemical compound C1=CC2=C3N(CC(C)(C)O)C(CCOC)=NC3=C(N)N=C2C=C1C1=CC=CC(NS(C)(=O)=O)=C1 SBHDTQQLGBQXLR-UHFFFAOYSA-N 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 201000008026 nephroblastoma Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 229960002700 octreotide Drugs 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 231100000205 reproductive and developmental toxicity Toxicity 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- LNQMAGOUQKHYNT-UHFFFAOYSA-N sulfanylidenemethylidenehydrazine Chemical group NN=C=S LNQMAGOUQKHYNT-UHFFFAOYSA-N 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 2
- 125000005309 thioalkoxy group Chemical group 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- HDZZVAMISRMYHH-KCGFPETGSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HDZZVAMISRMYHH-KCGFPETGSA-N 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 2
- 229960002730 vapreotide Drugs 0.000 description 2
- 108700029852 vapreotide Proteins 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 229940033942 zoladex Drugs 0.000 description 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- UFIVODCEJLHUTQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-(1-phenylethyldisulfanyl)-2h-pyridine-1-carboxylate Chemical compound C=1C=CC=CC=1C(C)SSC1C=CC=CN1C(=O)ON1C(=O)CCC1=O UFIVODCEJLHUTQ-UHFFFAOYSA-N 0.000 description 1
- VQZYZXLBKBUOHE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)butanoate Chemical compound C=1C=CC=NC=1SSC(C)CC(=O)ON1C(=O)CCC1=O VQZYZXLBKBUOHE-UHFFFAOYSA-N 0.000 description 1
- BSPMWFRGZQDRIU-UHFFFAOYSA-N (2-amino-1h-imidazol-5-yl)methanol Chemical class NC1=NC(CO)=CN1 BSPMWFRGZQDRIU-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- KYJLJOJCMUFWDY-UUOKFMHZSA-N (2r,3r,4s,5r)-2-(6-amino-8-azidopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound [N-]=[N+]=NC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O KYJLJOJCMUFWDY-UUOKFMHZSA-N 0.000 description 1
- RIFDKYBNWNPCQK-IOSLPCCCSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-imino-3-methylpurin-9-yl)oxolane-3,4-diol Chemical compound C1=2N(C)C=NC(=N)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RIFDKYBNWNPCQK-IOSLPCCCSA-N 0.000 description 1
- ZFPKPFDUWUEXOZ-SJEAMFKXSA-N (2s)-2-(cyclohexylamino)propanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@H](C)NC1CCCCC1 ZFPKPFDUWUEXOZ-SJEAMFKXSA-N 0.000 description 1
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 description 1
- LAXXPOJCFVMVAX-ZETCQYMHSA-N (2s)-2-amino-4-butylsulfanylbutanoic acid Chemical compound CCCCSCC[C@H](N)C(O)=O LAXXPOJCFVMVAX-ZETCQYMHSA-N 0.000 description 1
- HOVQQFUTZFIEIT-LMECJBHSSA-N (2s)-2-amino-4-phenylbutanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC1=CC=CC=C1 HOVQQFUTZFIEIT-LMECJBHSSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- STGXGJRRAJKJRG-JDJSBBGDSA-N (3r,4r,5r)-5-(hydroxymethyl)-3-methoxyoxolane-2,4-diol Chemical compound CO[C@H]1C(O)O[C@H](CO)[C@H]1O STGXGJRRAJKJRG-JDJSBBGDSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- RKSLVDIXBGWPIS-UAKXSSHOSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 RKSLVDIXBGWPIS-UAKXSSHOSA-N 0.000 description 1
- QLOCVMVCRJOTTM-TURQNECASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 QLOCVMVCRJOTTM-TURQNECASA-N 0.000 description 1
- AVKSPBJBGGHUMW-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-4-sulfanylidenepyrimidin-2-one Chemical compound O=C1NC(=S)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 AVKSPBJBGGHUMW-XLPZGREQSA-N 0.000 description 1
- MXHRCPNRJAMMIM-ULQXZJNLSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidine-2,4-dione Chemical compound O=C1NC(=O)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 MXHRCPNRJAMMIM-ULQXZJNLSA-N 0.000 description 1
- RKHPJMXDRRZPGD-UHFFFAOYSA-N 1-[4-(4-amino-2-butylimidazo[4,5-c][1,5]naphthyridin-1-yl)butyl]-3-butylurea Chemical compound C1=CC=NC2=C3N(CCCCNC(=O)NCCCC)C(CCCC)=NC3=C(N)N=C21 RKHPJMXDRRZPGD-UHFFFAOYSA-N 0.000 description 1
- GRGBJCMHYKWROJ-UHFFFAOYSA-N 1-[4-(4-amino-2-butylimidazo[4,5-c][1,5]naphthyridin-1-yl)butyl]-3-cyclohexylurea Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=NC3=C2N1CCCCNC(=O)NC1CCCCC1 GRGBJCMHYKWROJ-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- ARARQWKFKMWCDL-UHFFFAOYSA-N 1-nitro-2-[(2-nitrophenyl)methoxymethyl]benzene Chemical group [O-][N+](=O)C1=CC=CC=C1COCC1=CC=CC=C1[N+]([O-])=O ARARQWKFKMWCDL-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- ITIRVXDSMXFTPW-UHFFFAOYSA-N 1H-imidazo[4,5-c]quinoline Chemical compound C1=CC=CC2=C(NC=N3)C3=CN=C21 ITIRVXDSMXFTPW-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- UFCRQKWENZPCAD-UHFFFAOYSA-N 2-(2-aminophenyl)propanamide Chemical compound NC(=O)C(C)C1=CC=CC=C1N UFCRQKWENZPCAD-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 description 1
- WEZDRVHTDXTVLT-GJZGRUSLSA-N 2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 WEZDRVHTDXTVLT-GJZGRUSLSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- QXPXILGITKUCLM-UHFFFAOYSA-N 2-benzylidenepropane-1,3-diol Chemical compound OCC(CO)=CC1=CC=CC=C1 QXPXILGITKUCLM-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 description 1
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 description 1
- 125000004610 3,4-dihydro-4-oxo-quinazolinyl group Chemical group O=C1NC(=NC2=CC=CC=C12)* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 1
- ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 description 1
- PRLDILURXJMICQ-UHFFFAOYSA-N 4-[(4-aminophenyl)methoxymethyl]aniline Chemical compound C1=CC(N)=CC=C1COCC1=CC=C(N)C=C1 PRLDILURXJMICQ-UHFFFAOYSA-N 0.000 description 1
- XXSIICQLPUAUDF-TURQNECASA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XXSIICQLPUAUDF-TURQNECASA-N 0.000 description 1
- HRDXGYQCVPZEJE-UAKXSSHOSA-N 4-amino-5-bromo-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(Br)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HRDXGYQCVPZEJE-UAKXSSHOSA-N 0.000 description 1
- WCVPFJVXEXJFLB-UHFFFAOYSA-N 4-aminobutanamide Chemical class NCCCC(N)=O WCVPFJVXEXJFLB-UHFFFAOYSA-N 0.000 description 1
- ZRFUZDDJSQVQBY-UHFFFAOYSA-N 4-chloro-3-nitroquinoline Chemical compound C1=CC=CC2=C(Cl)C([N+](=O)[O-])=CN=C21 ZRFUZDDJSQVQBY-UHFFFAOYSA-N 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 1
- ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 1
- BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 description 1
- UEHOMUNTZPIBIL-UUOKFMHZSA-N 6-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7h-purin-8-one Chemical compound O=C1NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UEHOMUNTZPIBIL-UUOKFMHZSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- RYYIULNRIVUMTQ-UHFFFAOYSA-N 6-chloroguanine Chemical compound NC1=NC(Cl)=C2N=CNC2=N1 RYYIULNRIVUMTQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- OAUKGFJQZRGECT-UUOKFMHZSA-N 8-Azaadenosine Chemical compound N1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OAUKGFJQZRGECT-UUOKFMHZSA-N 0.000 description 1
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010056951 Actinic cheilitis Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000005748 Aggressive Fibromatosis Diseases 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101710192393 Attachment protein G3P Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102100036008 CD48 antigen Human genes 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101710169873 Capsid protein G8P Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000000529 Costimulatory and Inhibitory T-Cell Receptors Human genes 0.000 description 1
- 108010041504 Costimulatory and Inhibitory T-Cell Receptors Proteins 0.000 description 1
- MIKUYHXYGGJMLM-UUOKFMHZSA-N Crotonoside Chemical compound C1=NC2=C(N)NC(=O)N=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O MIKUYHXYGGJMLM-UUOKFMHZSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010009504 Gly-Phe-Leu-Gly Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000945340 Homo sapiens Killer cell immunoglobulin-like receptor 2DS1 Proteins 0.000 description 1
- 101000945339 Homo sapiens Killer cell immunoglobulin-like receptor 2DS2 Proteins 0.000 description 1
- 101000945342 Homo sapiens Killer cell immunoglobulin-like receptor 2DS4 Proteins 0.000 description 1
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 1
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 108010042653 IgA receptor Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 101150069255 KLRC1 gene Proteins 0.000 description 1
- 102100033631 Killer cell immunoglobulin-like receptor 2DS1 Human genes 0.000 description 1
- 102100033630 Killer cell immunoglobulin-like receptor 2DS2 Human genes 0.000 description 1
- 102100033624 Killer cell immunoglobulin-like receptor 2DS4 Human genes 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 231100000416 LDH assay Toxicity 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 101710156564 Major tail protein Gp23 Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- DXPCICLRJCAECX-ZETCQYMHSA-N NCCC(=O)NCCCC[C@H](N)C(O)=O Chemical compound NCCC(=O)NCCCC[C@H](N)C(O)=O DXPCICLRJCAECX-ZETCQYMHSA-N 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 1
- MRWXACSTFXYYMV-UHFFFAOYSA-N Nebularine Natural products OC1C(O)C(CO)OC1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102100021010 Nucleolin Human genes 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- 229910003849 O-Si Inorganic materials 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 229910003872 O—Si Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- RFCVXVPWSPOMFJ-STQMWFEESA-N Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 RFCVXVPWSPOMFJ-STQMWFEESA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001273 Polyhydroxy acid Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920002396 Polyurea Polymers 0.000 description 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 1
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 229930185560 Pseudouridine Natural products 0.000 description 1
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108091005685 RIG-I-like receptors Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108091027076 Spiegelmer Proteins 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 102100026966 Thrombomodulin Human genes 0.000 description 1
- 108010060888 Toll-like receptor 2 Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- VFCYZPOEGWLYRM-QCZKYFFMSA-N [(2s,3r,5s)-5-(4-amino-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] (2s)-2-amino-3-methylbutanoate Chemical compound O1[C@@H](CO)[C@H](OC(=O)[C@@H](N)C(C)C)C[C@H]1N1C(=O)N=C(N)C=C1 VFCYZPOEGWLYRM-QCZKYFFMSA-N 0.000 description 1
- HYSPJPGXSALJRR-DHIFEGFHSA-N [4-[[(2s)-5-(carbamoylamino)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl (4-nitrophenyl) carbonate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC=1C=CC(COC(=O)OC=2C=CC(=CC=2)[N+]([O-])=O)=CC=1)C(=O)CCCCCN1C(=O)C=CC1=O HYSPJPGXSALJRR-DHIFEGFHSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 125000005237 alkyleneamino group Chemical group 0.000 description 1
- 125000005238 alkylenediamino group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000005529 alkyleneoxy group Chemical group 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 125000005165 aryl thioxy group Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000005208 blood dendritic cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000316 bone substitute Substances 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- OWIUPIRUAQMTTK-UHFFFAOYSA-N carbazic acid Chemical class NNC(O)=O OWIUPIRUAQMTTK-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- MSPRUJDUTKRMLM-UHFFFAOYSA-N caroverine Chemical compound O=C1N(CCN(CC)CC)C2=CC=CC=C2N=C1CC1=CC=C(OC)C=C1 MSPRUJDUTKRMLM-UHFFFAOYSA-N 0.000 description 1
- 229960003355 caroverine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004323 caveolae Anatomy 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- OKYYOKGIPDRZJA-CPSXWDTOSA-N chembl2103792 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 OKYYOKGIPDRZJA-CPSXWDTOSA-N 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- GICLSALZHXCILJ-UHFFFAOYSA-N ctk5a5089 Chemical compound NCC(O)=O.NCC(O)=O GICLSALZHXCILJ-UHFFFAOYSA-N 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- KQWGXHWJMSMDJJ-UHFFFAOYSA-N cyclohexyl isocyanate Chemical compound O=C=NC1CCCCC1 KQWGXHWJMSMDJJ-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 125000006003 dichloroethyl group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000004609 dihydroquinazolinyl group Chemical group N1(CN=CC2=CC=CC=C12)* 0.000 description 1
- HXITXNWTGFUOAU-UHFFFAOYSA-N dihydroxy-phenylborane Natural products OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003118 drug derivative Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 208000023965 endometrium neoplasm Diseases 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000004615 furo[2,3-b]pyridinyl group Chemical group O1C(=CC=2C1=NC=CC2)* 0.000 description 1
- 125000004613 furo[2,3-c]pyridinyl group Chemical group O1C(=CC=2C1=CN=CC2)* 0.000 description 1
- 125000006086 furo[3,2-b]pyridinyl] group Chemical group 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229950009672 glembatumumab vedotin Drugs 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 102000045715 human TLR7 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 108010018844 interferon type III Proteins 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 1
- 210000004901 leucine-rich repeat Anatomy 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- HNQIVZYLYMDVSB-NJFSPNSNSA-N methanesulfonamide Chemical compound [14CH3]S(N)(=O)=O HNQIVZYLYMDVSB-NJFSPNSNSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003039 myelosuppressive effect Effects 0.000 description 1
- AMKBTTRWLGVRER-OFVILXPXSA-N n-[(2s)-1-[[(2s)-5-(carbamoylamino)-1-[4-(hydroxymethyl)anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-6-(2,5-dioxopyrrol-1-yl)hexanamide Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC=1C=CC(CO)=CC=1)C(=O)CCCCCN1C(=O)C=CC1=O AMKBTTRWLGVRER-OFVILXPXSA-N 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- OWIUPIRUAQMTTK-UHFFFAOYSA-M n-aminocarbamate Chemical compound NNC([O-])=O OWIUPIRUAQMTTK-UHFFFAOYSA-M 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical class [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical class C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002063 nanoring Substances 0.000 description 1
- 239000002078 nanoshell Substances 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 108010044762 nucleolin Proteins 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229950007318 ozogamicin Drugs 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001218 pegademase Drugs 0.000 description 1
- 108010027841 pegademase bovine Proteins 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 125000001147 pentyl group Chemical class C(CCCC)* 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 108010073101 phenylalanylleucine Proteins 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 208000022131 polyp of large intestine Diseases 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- ZQBJRISWRGSBDT-UHFFFAOYSA-N propane-1,1-diol;pyrrole-2,5-dione Chemical compound CCC(O)O.O=C1NC(=O)C=C1 ZQBJRISWRGSBDT-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 229940124553 radioprotectant Drugs 0.000 description 1
- 229920013730 reactive polymer Polymers 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- HNMATTJJEPZZMM-BPKVFSPJSA-N s-[(2r,3s,4s,6s)-6-[[(2r,3s,4s,5r,6r)-5-[(2s,4s,5s)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2s,5z,9r,13e)-13-[2-[[4-[(2e)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 1
- RHFUOMFWUGWKKO-UHFFFAOYSA-N s2C Natural products S=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 RHFUOMFWUGWKKO-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 150000007659 semicarbazones Chemical class 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000005555 sulfoximide group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000006092 tetrahydro-1,1-dioxothienyl group Chemical group 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000006090 thiamorpholinyl sulfone group Chemical group 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 150000003583 thiosemicarbazides Chemical class 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- PYHOFAHZHOBVGV-UHFFFAOYSA-N triazane Chemical compound NNN PYHOFAHZHOBVGV-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- SYHDSBBKRLVLFF-UHFFFAOYSA-N triparanol Chemical class C1=CC(OCCN(CC)CC)=CC=C1C(O)(C=1C=CC(C)=CC=1)CC1=CC=C(Cl)C=C1 SYHDSBBKRLVLFF-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 239000003744 tubulin modulator Substances 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- 229950002819 valtorcitabine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
本出願は、2014年1月10日に全て出願された中国特許出願第201410011324.5号、同201410011262.8号、及び同201410011362.0号の利益、及び同出願に対する優先権を主張し、これらの出願の全開示は、その全体が参照により本明細書に組み込まれる。
本発明は、標的免疫療法のための化合物、ならびにそれらを含む組成物に関する。さらに、本発明は、癌などの疾患の処置における当該化合物の使用に関する。
TM-Ln-AM(Ia)の構造を有する化合物を提供し、
式中、TMは、標的部分であり、AMは、樹状細胞、マクロファージ、単核球、骨髄由来抑制細胞、NK細胞、B細胞、T細胞または腫瘍細胞、またはそれらの組み合わせを含むがこれらに限定されないヒト免疫細胞を活性化させることができる活性化部分であり、Lnはリンカーであり、nは0及び1から選択される整数である。
TM-L-AM(Ib)
の構造を有する化合物、またはその薬学的に許容され得る塩または溶媒和物を提供し、
式中、TMは標的部分であり、Lはリンカーであり、AMは式(I):
式中、破線は結合または結合の不在を表し、
Xは、Sまたは-NR1であり、R1は-W0―W1―W2―W3―W4であり、
W0は、結合、アルキル、アルケニル、アルキニル、アルコキシ、または-アルキル-S-アルキル--であり、
W1は、結合、--O--、または--NR2--であり、ここでR2は、水素、アルキルまたはアルケニルであり、
W2は、結合、--O--、--C(O)--、--C(S)--、または-S(O)2―であり、
W3は、結合、--NR3--であり、ここでR3は、水素、アルキルまたはアルケニルであり、
W4は、水素、アルキル、アルケニル、アルキニル、アルコキシ、シクロアルキル、アリール、アリールオキシ、ヘテロアリール、またはヘテロシクリルであり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、シクロアルキル、アリール、ヘテロアリール、ヘテロシクリル、--NH2、ニトロ、--アルキル-ヒドロキシル、--アルキル-アリール、--アルキル-ヘテロアリール、--アルキル-ヘテロシクリル、--O-R4、--O-アルキル-R4、--アルキル-O-R4、--C(O)-R4、--アルキル-C(O)-R4、--アルキル-C(O)-O-R4、--C(O)-O-R4、--S-R4、--S(O)2-R4、--NH-S(O)2-R4、--アルキル-S-R4、--アルキル-S(O)2-R4、--NHR4、--NR4R4、--NH-アルキル-R4、ハロゲン、--CN、--NO2、及び-SHからなる群より選択される1つまたは複数の置換基により任意選択的に置換され、ここでR4は独立して、水素、アルキル、アルケニル、--アルキル-ヒドロキシル、アリール、ヘテロアリール、ヘテロシクリル、またはハロアルキルであり;
Zは、水素、アルキル、アルケニル、アルキニル、アルコキシ、アリール、ハロアルキル、ヘテロアリール、ヘテロシクリルであり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、アリール、ヘテロアリール、ヘテロシクリル、ハロゲン、シアノ、ニトロ、--N(R5)2、--アルコキシ-アルキル、--アルコキシ-アルケニル、--C(O)-アルキル、--C(O)-O-アルキル、--O-C(O)-アルキル、--C(O)-N(R5)2、アリール、ヘテロアリール、--CO-アリール、及び-CO-ヘテロアリールからなる群より選択される1つまたは複数の置換基により任意選択的に置換されることができ、ここで各R5は独立して、水素、アルキル、ハロアルキル、--アルキル-アリール、または-アルキル-ヘテロアリールであり;
Rは、水素、アルキル、アルコキシ、ハロアルキル、ハロゲン、アリール、ヘテロアリール、ヘテロシクリルであり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、シクロアルキル、アリール、ヘテロアリール、ヘテロシクリル、--NH2、ニトロ、--アルキル-ヒドロキシル、--アルキル-アリール、--アルキル-ヘテロアリール、--アルキル-ヘテロシクリル、--O-R4、--O-アルキル-R4、--アルキル-O-R4、--C(O)-R4、--C(O)-NH-R4、--C(O)-NR4R4、--アルキル-C(O)-R4、--アルキル-C(O)-O-R4、--C(O)-O-R4、--O-C(O)-R4、--S-R4、--C(O)-S-R4、--S-C(O)-R4、--S(O)2-R4、--NH-S(O)2-R4、--アルキル-S-R4、--アルキル-S(O)2-R4、--NHR4、--NR4R4、--NH-アルキル-R4、ハロゲン、--CN、及び-SHからなる群より選択される1つまたは複数の置換基により任意選択的に置換され、ここでR4は独立して、水素、アルキル、アルケニル、アルコキシ、--アルキル-ヒドロキシル、アリール、ヘテロアリール、ヘテロシクリル、またはハロアルキルであり;
nは、0、1、2、3、または4であり;
Yは、-NR6R7、-CR6R7R8、または-アルキル-NH2であり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、--NH2、ハロゲン、--N(R5)2、--アルコキシ-アルキル、--アルコキシ-アルケニル、--C(O)-アルキル、--C(O)-O-アルキル、--C(O)-N(R5)2、アリール、ヘテロアリール、--CO-アリール、及び-CO-ヘテロアリールからなる群より選択される1つまたは複数の置換基により任意選択的に置換されることができ、
ここでR6、R7及びR8は独立して、水素、アルキル、アルケニル、アルコキシ、アルキルアミノ、ジアルキルアミノ、アルキルチオ、アリールチオ、--アルキル-ヒドロキシル、--アルキル-C(O)-O-R9、--アルキル-C(O)-R9、または-アルキル-O-C(O)-R9であり、ここで各R5は独立して、水素、アルキル、ハロアルキル、--アルキル-アリール、または-アルキル-ヘテロアリールであり、ここでR9は、水素、アルキル、アルケニル、ハロゲン、またはハロアルキルであり;
X及びZは一緒になって、任意選択的に(5~9)員環を形成し得る。
mは1、2、3、4、5、または6であり、各bは独立して、0または1であり、Dは独立して、式(III):
の構造により表され、
式中、各iは独立して、0または1であり;
各jは独立して、0、1、2、3、4、5、または6であり;
各Aは独立して、S、O、またはN-Raであり、ここでRaは、水素、アルキル、アルケニル、またはアルコキシであり;
各Bは独立して、アルキル、アルケニル、--O-アルキル-、--アルキル-O--、--S-アルキル--、--アルキル-S--、アリール、ヘテロアリール、ヘテロシクリル、またはペプチドであり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、シクロアルキル、--アルキル-アリール、--アルキル-ヘテロアリール、--アルキル-ヘテロシクリル、--O-R4、--O-アルキル-R4、--C(O)-R4、--C(O)-O-R4、--S-R4、--S(O)2-R4、--NHR4、--NH-アルキル-R4、ハロゲン、--CN、--NO2、及び-SHからなる群より選択される1つまたは複数の置換基により任意選択的に置換され、ここでR4は、アルキル、アルケニル、--アルキル-ヒドロキシル、アリール、ヘテロアリール、ヘテロシクリル、またはハロアルキルである。
TM-L-AM(Ib)
の構造を有する化合物、またはその薬学的に許容され得る塩または溶媒和物を提供し、
式中、TMは標的部分であり、Lはリンカーであり、AMは式(IV):
式中、
Vは、-NR6R7であり、R6及びR7のそれぞれは独立して、水素、アルキル、アルケニル、アルコキシ、アルキルアミノ、ジアルキルアミノ、アルキルチオ、アリールチオ、--アルキル-ヒドロキシル、--アルキル-C(O)-O-R9、--アルキル-C(O)-R9、または-アルキル-O-C(O)-R9であり、ここでR9は、水素、アルキル、アルケニル、ハロゲン、またはハロアルキルであり;
R10及びR11は独立して、水素、アルキル、アルケニル、アリール、ハロアルキル、ヘテロアリール、ヘテロシクリル、またはシクロアルキルであり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、ハロゲン、--N(R5)2、--アルコキシ-アルキル、--アルコキシ-アルケニル、--C(O)-アルキル、--C(O)-O-アルキル、--C(O)-N(R5)2、アリール、ヘテロアリール、--CO-アリール、及び-CO-ヘテロアリールからなる群より選択される1つまたは複数の置換基により任意選択的に置換され、ここで各R5は独立して、水素、アルキル、ハロアルキル、--アルキル-アリール、または-アルキル-ヘテロアリールであり;TM及びLは、上記及び下記に定義される。
本明細書で言及する全ての刊行物、特許、及び特許出願は、各個別の刊行物、特許、または特許出願は、ここで具体的及び個別に参照により組み込まれるように示されるのと同程度に、参照により組み込まれる。
別段の定義のない限り、本明細書において使用される全ての技術用語及び科学用語は、一般に、本発明が属する当業者により一般的に理解されるものと同じ意味を有する。一般に、本明細書、及び細胞培養、分子遺伝学、有機化学、及び核酸化学及びハイブリダイゼーションにおける実験室手順に使用される命名法は、当該分野において周知であり、一般的に用いられているものである。標準的な技術が、核酸及びペプチド合成に使用される。技術及び手順は、当該分野における従来の方法、及びこの文書の全体を通して提供される種々の一般的な参照に従って一般に実施される。本明細書、及び分析化学における実験室手順、及び下記に記載されている有機合成に使用される命名法は、当該分野において周知のものであり、一般的に用いられるものである。標準的な技術またはそれらの修正が、化学合成及び化学分析に使用される。
(a)アルキル;
(b)ヒドロキシ(または保護されたヒドロキシ);
(c)ハロ;
(d)オキソ、すなわち、=O;
(e)アミノ、アルキルアミノまたはジアルキルアミノ;
(f)アルコキシ;
(g)シクロアルキル;
(h)カルボキシ;
(i)ヘテロシクロオキシ、ここでヘテロシクロオキシは酸素架橋を通して結合された複素環基を示す;
(j)アルキル-O-C(O)--;
(k)メルカプト;
(l)ニトロ;
(m)シアノ;
(n)スルファモイルまたはスルホンアミド;
(o)アリール;
(p)アルキル-C(O)-O--;
(q)アリール-C(O)-O--;
(r)アリール-S--;
(s)アリールオキシ;
(t)アルキル-S--;
(u)ホルミル、すなわち、HC(O)--;
(v)カルバモイル;
(w)アリール-アルキル--;及び
(x)アルキル、シクロアルキル、アルコキシ、ヒドロキシ、アミノ、アルキル-C(O)-NH--、アルキルアミノ、ジアルキルアミノまたはハロゲンで置換されたアリール。
一態様では、本発明は式(Ia):
TM-Ln-AM(Ia)の構造を有する化合物を提供し、
式中、TMは標的部分であり、AMは、樹状細胞、ナチュラルキラー細胞、または腫瘍細胞、またはそれらの組み合わせを活性化させる活性化部分であり、Lnはリンカーであり、nは0及び1から選択される整数である。
TM-L-AM(Ib)
の構造を有する化合物、またはその薬学的に許容され得る塩または溶媒和物を提供し、
式中、TMは標的部分であり、Lはリンカーであり、AMは式(I):
式中、破線は結合または結合の不在を表し、
Xは、Sまたは-NR1であり、R1は-W0―W1―W2―W3―W4であり、
W0は、結合、アルキル、アルケニル、アルキニル、アルコキシ、または-アルキル-S-アルキル--であり、
W1は、結合、--O--、または--NR2--であり、ここでR2は、水素、アルキルまたはアルケニルであり、
W2は、結合、--O--、--C(O)--、--C(S)--、または-S(O)2―であり、
W3は、結合、--NR3--であり、ここでR3は、水素、アルキルまたはアルケニルであり、
W4は、水素、アルキル、アルケニル、アルキニル、アルコキシ、シクロアルキル、アリール、アリールオキシ、ヘテロアリール、またはヘテロシクリルであり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、シクロアルキル、アリール、ヘテロアリール、ヘテロシクリル、--NH2、ニトロ、--アルキル-ヒドロキシル、--アルキル-アリール、--アルキル-ヘテロアリール、--アルキル-ヘテロシクリル、--O-R4、--O-アルキル-R4、--アルキル-O-R4、--C(O)-R4、--アルキル-C(O)-R4、--アルキル-C(O)-O-R4、--C(O)-O-R4、--S-R4、--S(O)2-R4、--NH-S(O)2-R4、--アルキル-S-R4、--アルキル-S(O)2-R4、--NHR4、--NR4R4、--NH-アルキル-R4、ハロゲン、--CN、--NO2、及び-SHからなる群より選択される1つまたは複数の置換基により任意選択的に置換され、ここでR4は独立して、水素、アルキル、アルケニル、--アルキル-ヒドロキシル、アリール、ヘテロアリール、ヘテロシクリル、またはハロアルキルであり;
Zは、水素、アルキル、アルケニル、アルキニル、アルコキシ、アリール、ハロアルキル、ヘテロアリール、ヘテロシクリルであり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、アリール、ヘテロアリール、ヘテロシクリル、ハロゲン、シアノ、ニトロ、--N(R5)2、--アルコキシ-アルキル、--アルコキシ-アルケニル、--C(O)-アルキル、--C(O)-O-アルキル、--O-C(O)-アルキル、--C(O)-N(R5)2、アリール、ヘテロアリール、--CO-アリール、及び-CO-ヘテロアリールからなる群より選択される1つまたは複数の置換基により任意選択的に置換されることができ、ここで各R5は独立して、水素、アルキル、ハロアルキル、--アルキル-アリール、または-アルキル-ヘテロアリールであり;
Rは、水素、アルキル、アルコキシ、ハロアルキル、ハロゲン、アリール、ヘテロアリール、ヘテロシクリルであり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、シクロアルキル、アリール、ヘテロアリール、ヘテロシクリル、--NH2、ニトロ、--アルキル-ヒドロキシル、--アルキル-アリール、--アルキル-ヘテロアリール、--アルキル-ヘテロシクリル、--O-R4、--O-アルキル-R4、--アルキル-O-R4、--C(O)-R4、--C(O)-NH-R4、--C(O)-NR4R4、--アルキル-C(O)-R4、--アルキル-C(O)-O-R4、--C(O)-O-R4、--O-C(O)-R4、--S-R4、--C(O)-S-R4、--S-C(O)-R4、--S(O)2-R4、--NH-S(O)2-R4、--アルキル-S-R4、--アルキル-S(O)2-R4、--NHR4、--NR4R4、--NH-アルキル-R4、ハロゲン、--CN、及び-SHからなる群より選択される1つまたは複数の置換基により任意選択的に置換され、ここでR4は独立して、水素、アルキル、アルケニル、アルコキシ、--アルキル-ヒドロキシル、アリール、ヘテロアリール、ヘテロシクリル、またはハロアルキルであり;
nは、0、1、2、3、または4であり;
Yは、-NR6R7、-CR6R7R8、または-アルキル-NH2であり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、--NH2、ハロゲン、--N(R5)2、--アルコキシ-アルキル、--アルコキシ-アルケニル、--C(O)-アルキル、--C(O)-O-アルキル、--C(O)-N(R5)2、アリール、ヘテロアリール、--CO-アリール、及び-CO-ヘテロアリールからなる群より選択される1つまたは複数の置換基により任意選択的に置換されることができ、
ここでR6、R7及びR8は独立して、水素、アルキル、アルケニル、アルコキシ、アルキルアミノ、ジアルキルアミノ、アルキルチオ、アリールチオ、--アルキル-ヒドロキシル、--アルキル-C(O)-O-R9、--アルキル-C(O)-R9、または-アルキル-O-C(O)-R9であり、ここで各R5は独立して、水素、アルキル、ハロアルキル、--アルキル-アリール、または-アルキル-ヘテロアリールであり、ここでR9は、水素、アルキル、アルケニル、ハロゲン、またはハロアルキルであり;
X及びZは一緒になって、任意選択的に(5~9)員環を形成し得る。
TM-L-AM(Ib)、
の構造を有する化合物、またはそれらの薬学的に許容され得る塩または溶媒和物を提供し、
式中、TMは標的部分であり、Lはリンカーであり、AMは式(Ic):
式中、破線は結合または結合の不在を表し、
R1は、-W0―W1―W2―W3―W4であり、
W0は、結合、アルキル、アルケニル、アルキニル、アルコキシ、または-アルキル-S-アルキル--であり、
W1は、結合、--O--、または--NR2--であり、ここでR2は、水素、アルキルまたはアルケニルであり、
W2は、結合、--O--、--C(O)--、--C(S)--、または-S(O)2―であり、
W3は、結合、--NR3--であり、ここでR3は、水素、アルキルまたはアルケニルであり、
W4は、水素、アルキル、アルケニル、アルキニル、アルコキシ、シクロアルキル、アリール、アリールオキシ、ヘテロアリール、またはヘテロシクリルであり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、シクロアルキル、アリール、ヘテロアリール、ヘテロシクリル、--NH2、ニトロ、--アルキル-ヒドロキシル、--アルキル-アリール、--アルキル-ヘテロアリール、--アルキル-ヘテロシクリル、--O-R4、--O-アルキル-R4、--アルキル-O-R4、--C(O)-R4、--アルキル-C(O)-R4、--アルキル-C(O)-O-R4、--C(O)-O-R4、--S-R4、--S(O)2-R4、--NH-S(O)2-R4、--アルキル-S-R4、--アルキル-S(O)2-R4、--NHR4、--NR4R4、--NH-アルキル-R4、ハロゲン、--CN、--NO2、及び-SHからなる群より選択される1つまたは複数の置換基により任意選択的に置換され、ここでR4は独立して、水素、アルキル、アルケニル、--アルキル-ヒドロキシル、アリール、ヘテロアリール、ヘテロシクリル、またはハロアルキルであり;
Zは、水素、アルキル、アルケニル、アルキニル、アルコキシ、アリール、ハロアルキル、ヘテロアリール、ヘテロシクリルであり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、アリール、ヘテロアリール、ヘテロシクリル、ハロゲン、シアノ、ニトロ、--N(R5)2、--アルコキシ-アルキル、--アルコキシ-アルケニル、--C(O)-アルキル、--C(O)-O-アルキル、--O-C(O)-アルキル、--C(O)-N(R5)2、アリール、ヘテロアリール、--CO-アリール、及び-CO-ヘテロアリールからなる群より選択される1つまたは複数の置換基により任意選択的に置換されることができ、ここで各R5は独立して、水素、アルキル、ハロアルキル、--アルキル-アリール、または-アルキル-ヘテロアリールであり;
Rは、水素、アルキル、アルコキシ、ハロアルキル、ハロゲン、アリール、ヘテロアリール、ヘテロシクリルであり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、シクロアルキル、アリール、ヘテロアリール、ヘテロシクリル、--NH2、ニトロ、--アルキル-ヒドロキシル、--アルキル-アリール、--アルキル-ヘテロアリール、--アルキル-ヘテロシクリル、--O-R4、--O-アルキル-R4、--アルキル-O-R4、--C(O)-R4、--C(O)-NH-R4、--C(O)-NR4R4、--アルキル-C(O)-R4、--アルキル-C(O)-O-R4、--C(O)-O-R4、--O-C(O)-R4、--S-R4、--C(O)-S-R4、--S-C(O)-R4、--S(O)2-R4、--NH-S(O)2-R4、--アルキル-S-R4、--アルキル-S(O)2-R4、--NHR4、--NR4R4、--NH-アルキル-R4、ハロゲン、--CN、及び-SHからなる群より選択される1つまたは複数の置換基により任意選択的に置換され、ここでR4は独立して、水素、アルキル、アルケニル、アルコキシ、--アルキル-ヒドロキシル、アリール、ヘテロアリール、ヘテロシクリル、またはハロアルキルであり;
nは、0、1、2、3、または4であり;
Yは、-NR6R7、-CR6R7R8、または-アルキル-NH2であり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、--NH2、ハロゲン、--N(R5)2、--アルコキシ-アルキル、--アルコキシ-アルケニル、--C(O)-アルキル、--C(O)-O-アルキル、--C(O)-N(R5)2、アリール、ヘテロアリール、--CO-アリール、及び-CO-ヘテロアリールからなる群より選択される1つまたは複数の置換基により任意選択的に置換されることができ、
ここでR6、R7及びR8は独立して、水素、アルキル、アルケニル、アルコキシ、アルキルアミノ、ジアルキルアミノ、アルキルチオ、アリールチオ、--アルキル-ヒドロキシル、--アルキル-C(O)-O-R9、--アルキル-C(O)-R9、または-アルキル-O-C(O)-R9であり、ここで各R5は独立して、水素、アルキル、ハロアルキル、--アルキル-アリール、または-アルキル-ヘテロアリールであり、ここでR9は、水素、アルキル、アルケニル、ハロゲン、またはハロアルキルであり;
X及びZは一緒になって、任意選択的に(5~9)員環を形成し得る。
TM-L-AM(Ib)
の構造を有する化合物、またはその薬学的に許容され得る塩または溶媒和物を提供し、
式中、TMは標的部分であり、Lはリンカーであり、AMは式(IV):
式中、
Vは、-NR6R7であり、R6及びR7のそれぞれは独立して、水素、アルキル、アルケニル、アルコキシ、アルキルアミノ、ジアルキルアミノ、アルキルチオ、アリールチオ、--アルキル-ヒドロキシル、--アルキル-C(O)-O-R9、--アルキル-C(O)-R9、または-アルキル-O-C(O)-R9であり、ここでR9は、水素、アルキル、アルケニル、ハロゲン、またはハロアルキルであり;
R10及びR11は独立して、水素、アルキル、アルケニル、アリール、ハロアルキル、ヘテロアリール、ヘテロシクリル、またはシクロアルキルであり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、ハロゲン、--N(R5)2、--アルコキシ-アルキル、--アルコキシ-アルケニル、--C(O)-アルキル、--C(O)-O-アルキル、--C(O)-N(R5)2、アリール、ヘテロアリール、--CO-アリール、及び-CO-ヘテロアリールからなる群より選択される1つまたは複数の置換基により任意選択的に置換され、ここで各R5は独立して、水素、アルキル、ハロアルキル、--アルキル-アリール、または-アルキル-ヘテロアリールであり;
TM及びLは、上記及び下記に定義される。
式中、Rは、―NH(R5)及びイソチオシアネート(―NCS)からなる群より選択され;
R5は、水素(―H)、アセチル、―CO-tert-Bu(-Boc)、―CO―(CH2)X―R6、C1~C16アルキル、―CO-4-(フェニルボロン酸)、―C(S)―NH―(CH2)X―NH―(CH2)X―NH―(CH2)X―NH2、
R6は、水素、アルキン、アジド、カルボン酸、及び―CONH―(CH2)X―O―(CH2)X―O―(CH2)X―O―(CH2)X―R7からなる群より選択され;
R7は、アミノ、イソチオシアネート、及び―NH―CO―(CH2)X―CO2Hからなる群より選択され;
R8は、ペプチド抗原部分またはタンパク質抗原部分から選択され;
xは、1から10の任意の整数である。
式中、R1及びR3はそれぞれ独立して、水素、ハロゲン、ニトロ、―NH2、アジド、ヒドロキシル、―CF3、カルボン酸(carboylic acid)、及び―CO2R2からなる群より選択され;
R2は、C2~C5アルキルであり、
R4は、―NH(R5)及びイソチオシアネートからなる群より選択され;
R5は、水素、アセチル、―CO-tert-Bu(-Boc)、―CO―(CH2)X―R6、C1~C16アルキル、―CO-4-(フェニルボロン酸)、―C(S)―NH―(CH2)X―NH―(CH2)X―NH―(CH2)X―NH2、
R6は、水素、アルキン、アジド、カルボン酸、及び―CONH―(CH2)X―O―(CH2)X―O―(CH2)X―O―(CH2)X―R7からなる群より選択され;
R7は、アミノ、イソチオシアネート、及び―NH―CO―(CH2)X―CO2Hからなる群より選択され;
R8は、ペプチド抗原部分またはタンパク質抗原部分から選択され;
Xは、1から10の任意の整数である。その開示がその全体において参照により組み込まれる、米国特許出願公開第20140256922A1。
一般に、本発明の化合物は、標的部分を含む。
一般に、本発明の化合物は、標的部分と活性化部分を結合するリンカーを含む。しかし、いくつかの化合物において、リンカーが存在せず、活性化部分と標的部分は直接結合する。
-Ta-Ww-Yy-
を有し、
式中、-T-は、ストレッチャー単位であり;aは、0または1であり;各-W-は独立して、アミノ酸単位であり;wは、独立して2~12の範囲の整数であり;-Y-は、スペーサー単位であり;yは、0、1、または2である。
ストレッチャー単位(-T-)は、存在する場合、標的部分をアミノ酸単位(-W-)に結合させる。天然型または化学操作を介したいずれかの抗体などの標的部分に存在し得る有用な官能基には、スルフヒドリル、アミノ、ヒドロキシル、炭水化物のアノマーヒドロキシル基、及びカルボキシルが含まれるが、これらに限定されない。好適な官能基は、スルフヒドリル及びアミノである。スルフヒドリル基は、抗体の分子内ジスルフィド結合の還元により生成することができる。あるいは、スルフヒドリル基は、抗体のリシン部分のアミノ基と、2-イミノチオラン(トラウト試薬)または他のスルフヒドリル生成試薬との反応により、生成することができる。いくつかの実施形態では、抗体は、組み換え抗体であり、1つまたは複数のリシンを有するように操作される。他の実施形態では、組み換え抗体は、追加のスルフヒドリル基、例えば追加のシステインを有するように操作される。
アミノ酸単位(-W-)は、スペーサー単位が存在する場合には、ストレッチャー単位(-T-)をスペーサー単位(-Y-)に結合させ、スペーサー単位が不在の場合には、ストレッチャー単位を細胞障害剤または細胞増殖抑制剤(活性化部分;D)に結合させる。-Ww-は、ジペプチド、トリペプチド、テトラペプチド、ペンタペプチド、ヘキサペプチド、ヘプタペプチド、オクタペプチド、ノナペプチド、デカペプチド、ウンデカペプチド、またはドデカペプチド単位である。各-W-単位は、独立して、角括弧内に下記に示す式:
式中、R2は、水素、メチル、イソプロピル、イソブチル、sec-ブチル、ベンジル、p-ヒドロキシベンジル、―CH2OH、―CH(OH)CH3、―CH2CH2SCH3、―CH2CONH2、―CH2COOH、―CH2CH2CONH2、―CH2CH2COOH、―(CH2)3NHC(=NH)NH2、―(CH2)3NH2、―(CH2)3NHCOCH3、―(CH2)3NHCHO、―(CH2)4NHC(=NH)NH2、―(CH2)4NH2、―(CH2)4NHCOCH3、―(CH2)4NHCHO、―(CH2)3NHCONH2、―(CH2)4NHCONH2、―CH2CH2CH(OH)CH2NH2、2-ピリジルメチル-、3-ピリジルメチル-、4-ピリジルメチル-、フェニル、シクロヘキシル、
スペーサー単位(-Y-)は、存在する場合、アミノ酸単位を薬物単位に結合させる。スペーサー単位には、自己犠牲型及び非自己犠牲型の2つの一般的な種類がある。非自己犠牲型スペーサー単位は、スペーサー単位の一部または全てが、TM-リンカー-AMコンジュゲートまたは薬物-リンカー化合物からのアミノ酸単位の酵素切断の後、活性化部分単位に結合したままであるものである。非自己犠牲型スペーサー単位の例には、(グリシン-グリシン)スペーサー単位及びグリシンスペーサー単位が挙げられるが、これらに限定されない。グリシン-グリシンスペーサー単位またはグリシンスペーサー単位を含有するTM-リンカー-AMコンジュゲートが、腫瘍細胞関連プロテアーゼ、癌細胞関連プロテアーゼ、またはリンパ球関連プロテアーゼを介して酵素切断を受ける場合、グリシン-グリシン-薬物部分またはグリシン-薬物部分は、A-T-Ww-から切断される。AMを遊離するため、独立した加水分解反応が、グリシン-薬物単位結合を切断するために標的細胞内で生じるべきである。
式中、Qは、C1~C8アルキル、C1~C8アルコキシ、ハロゲン、ニトロ、またはシアノであり;mは、0~4の範囲の整数である。
の構造により表され、mは、1、2、3、4、5、または6であり、各bは独立して、0または1であり、Dは独立して、式(III):
式中、各iは独立して、0または1であり;
各jは独立して、0、1、2、3、4、5、または6であり;
各Aは独立して、S、O、またはN-Raであり、ここでRaは、水素、アルキル、アルケニル、またはアルコキシであり;
各Bは独立して、アルキル、アルケニル、--O-アルキル-、--アルキル-O--、--S-アルキル--、--アルキル-S--、アリール、ヘテロアリール、ヘテロシクリル、またはペプチドであり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、シクロアルキル、--アルキル-アリール、--アルキル-ヘテロアリール、--アルキル-ヘテロシクリル、--O-R4、--O-アルキル-R4、--C(O)-R4、--C(O)-O-R4、--S-R4、--S(O)2-R4、--NHR4、--NH-アルキル-R4、ハロゲン、--CN、--NO2、及び-SHからなる群より選択される1つまたは複数の置換基により任意選択的に置換され、ここでR4は、アルキル、アルケニル、--アルキル-ヒドロキシル、アリール、ヘテロアリール、ヘテロシクリル、またはハロアルキルである。
一般に、式(I)の構造により表される活性化部分は、以下に概略する、合成手法を用いて作製することができる。ステップ(1)では、式Aの4-クロロ-3-ニトロキノリンを式R1NH2のアミンと反応させて式Bの3-ニトロキノリン-4-アミンを提供する。ステップ2では、式Bの3-ニトロキノリン-4-アミンを還元させて式Cのキノリン(quinoine)-3-4-ジアミンを提供する。ステップ3では、式Cのキノリン(quinoine)-3-4-ジアミンをカルボン酸またはその等価物と反応させて式Dの1H-イミダゾ[4,5c]キノリンを提供する。
本発明は、本明細書の化合物またはその薬学的に許容され得る塩、及び1つまたは複数の薬学的に許容され得る担体を含む、医薬製剤にさらに関する。
別の態様では、本発明は、1つまたは複数の本発明の化合物または組成物と、当該化合物または組成物の使用指示書とを含有するキットを提供する。例示的な実施形態では、本発明は、本発明のリンカーアームを別の分子とコンジュゲートするためのキットを提供する。キットは、リンカーと、リンカーを特定の官能基に付着させるための指示書とを含む。キットは、1つまたは複数の細胞障害薬、標的剤、検出可能標識、薬学的塩または緩衝液も含み得る。キットは、容器、及び任意選択的に1つまたは複数のバイアル、試験管、フラスコ、ボトル、またはシリンジも含み得る。キットの他の形式は、当業者に明白であり得、本発明の範囲内である。
別の態様では、本発明は、疾患状態の処置を必要とする対象内の疾患状態を処置するための方法であって、治療有効量の本発明の化合物、その薬学的に許容され得る塩、及び薬学的に許容され得る担体を含む医薬組成物を対象に投与することを含む、前記方法を提供する。
本発明での使用に好適な医薬組成物には、活性成分が治療有効量、すなわち、その意図される目的を達成するのに有効な量で含有される組成物が含まれる。特定の用途のための実際の有効量は、とりわけ、処置される状態に依存するだろう。有効量の決定は、特に本明細書の詳細な開示を考慮すると、十分に当業者の能力の範囲内である。
her2またはegfrトランスフェクトL細胞系の生成
試薬:L細胞は、ATCC(バージニア州マナサス;カタログ番号CRL2648)からのものであり、Her2/pEZ-Lv105またはegfr/pCMV cDNAは、Sino Biological Inc.,(カタログ番号H10004)またはGeneCopoeia(カタログ番号Z2866)から購入した、グルコースDMEM、L-グルタミン、リポフェクタミン2000(Invitrogen;カリフォルニア州カールスバッド)。
コンジュゲートトラスツズマブの結合能を決定するため、ヒトHer2を発現するL細胞のFACS分析を実施した。簡潔には、her2を一過的にトランスフェクトした100μl中おおよそ106個のL細胞を、様々な量のトラスツズマブコンジュゲート抗体と共にインキュベートし、PBSまたは二次抗体単独または無関係のhuIgGを陰性対照として使用した。洗浄後、細胞をFACS緩衝液に再懸濁し、100μLの反応容量中のフィコエリトリン(μ抗ヒトPE)二次抗体にコンジュゲートした20μLのマウス抗ヒトIgGと共に室温で30分間インキュベートした。洗浄後、細胞を200μLの2%パラホルムアルデヒド/PBSにて固定し、フローサイトメトリーを実施した。同じ手順をアイソタイプ対照として無関係のヒトIgG抗体に対して使用して、細胞系毎にベースラインPMTを設定した。フローサイトメトリーを、BD FACSCalibur(登録商標)により実施し、幾何平均蛍光強度をそれぞれの試料に対して記録した。記録したデータを、FlowJoソフトウエアを使用して分析した。結果を図1に示す。
試薬:トラスツズマブ(Roche/Genentech Corporation、カリフォルニア州サウスサンフランシスコ)、セツキシマブ(Merck)、レシキモドと結合したMC-val-cit-PAB(MC-vc-PAB-TLRL)またはレシキモドと結合したMC(MC-TLRL)(Contract Research Organization、中国において合成)、ホウ酸ナトリウム、塩化ナトリウム、ジチオスレイトール(DTT)、Sephadex G25、DTPA、DTNB、及びマレイミドカプロイル-モノメチル(Sigma-Aldrich、ウィスコンシン州ミルウォーキー)。
トラスツズマブを、20mg/mLでの緩衝液交換によりHERCEPTIN(登録商標)から精製し、pH8.0の500mMのホウ酸ナトリウム及び500mMの塩化ナトリウム中に溶解した抗体を、過剰量の100mMジチオスレイトール(DTT)で処理する。37℃で約30分間インキュベートした後、緩衝液をSephadex G25樹脂での溶出により交換し、1mMのDTPAを有するPBSで溶出する。チオール/Ab値は、溶液の280nmでの吸光度からの還元された抗体の濃度、及びDTNB(Sigma-Aldrich、ウィスコンシン州ミルウォーキー)との反応によるチオール濃度を決定すること、及び412nmにおける吸光度の決定によって、調べる。PBS中に溶解した還元抗体を氷上で冷却する。DMSO中に溶解した、レシキモドとMc結合した薬物リンカー試薬を、既知の濃度でアセトニトリル及び水中に希釈し、PBS中の冷却還元抗体に添加する。約1時間後、過剰量のマレイミドを添加して、反応をクエンチし、あらゆる未反応抗体チオール基をキャップする。いくつかの場合では、標準的な手順を用いた免疫グロブリンのリシンへの結合を実施した。反応混合物を遠心分離限外濾過により濃縮し、コンジュゲート抗体を精製し、PBS中でG25樹脂を通す溶出により脱塩し、0.2μmフィルターを通して滅菌条件下で濾過し、凍結保存する。セツキシマブMC-TLRLの調製は同じ手法を使用した。
抗体を、マレイミドカプロイル-バリン-シトルリン(vc)-p-アミノベンジルオキシカルボニル(MC-vc-PAB)によりシステインを通してTLRLに結合した。MC-vc-PABリンカーは、カテプシンBなどの細胞間プロテアーゼにより切断可能であり、切断されると、遊離薬物を放出し(Doroninaら、Nat.Biotechnol.,21:778-784(2003))、一方でMCリンカーは、細胞内プロテアーゼによる切断に対して抵抗性である。精製したトラスツブマブを、pH8.0の500mMのホウ酸ナトリウム及び500mMの塩化ナトリウム中に溶解し、過剰量の100MMジチオスレイトール(DTT)でさらに処理した。37℃で約30分間インキュベートした後、緩衝液をSephadex G25樹脂での溶出により交換し、1mMのDTPAを有するPBSで溶出する。チオール/Ab値を、溶液の280nmでの吸光度からの還元された抗体の濃度、及びDTNB(Sigma-Aldrich、ウィスコンシン州ミルウォーキー)との反応によるチオール濃度を決定すること、及び412nm(吸光係数=13600cm-1M-1)における吸光度の決定によって、調べた。PBS中に溶解した還元抗体を氷上で冷却した。DMSO中でレシキモドと結合したMC-val-cit-PAB-PNPを、アセトニトリル及び水中に溶解し、PBS中の冷却還元抗体に添加した。1時間のインキュベーションの後、過剰量のマレイミドを添加して、反応をクエンチし、あらゆる未反応抗体チオール基をキャップした。いくつかの場合では、標準的な手順を用いた免疫グロブリンのリシンへの結合を実施した。反応混合物を遠心分離限外濾過により濃縮し、抗体薬物複合体を精製し、PBS中でG25樹脂を通す溶出により脱塩し、0.2μmフィルターを通して滅菌条件下で濾過し、凍結保存した。セツキシマブMC-vc-TLRLの調製は同じ手法を使用した。
試薬:SKBR3細胞(ATCC、カタログ番号HTB-30)、マッコイ5A(Invitrogen、カタログ番号22400、ロット番号747809);RPMI-1640(Invitrogen、カタログ番号11835、ロット番号764956);FCS(Hyclone、カタログ番号SH30084.03、ロット番号GRH0054);フィコール・ハイパック(Amersham Biosciences、ニュージャージー州ピスカタウェイ;カタログ番号17-1440-02)、96ウエルプレート(Costar、カタログ番号3599、カタログ番号3916);トリパンブルー(Invitrogen カタログ番号15250-061);LDHキット(Promega、カタログ番号G7891)、ELISAリーダーMD5(Molecule device)、ヒト化抗体Herceptin(登録商標)(Genentech Corporation、カリフォルニア州サウスサンフランシスコ;トラスツズマブの商標名)は水で再構成して、使用前に10mg/mlの貯蔵液を作製した。
ヒトPBMCを、Ficoll遠心分離により、健常な志願提供者から得たバフィーコートから調製した。樹状細胞を、ヒトPBMCからの抗CD3、CD19、CD20、CD14、及びCD16抗体の混合物を伴う磁気ビーズ(Miltenyi Biotec)を用いる陰性枯渇を使用することにより濃縮した。DCの濃縮を、ヤギ抗マウスFITC(系列)、HLA-DR-APCCy7、CD123-BV421及びCD11C-APCで染色した。染色された細胞をBDLSR Fortessaにより分析した。抗CD3、CD4、CD11C、CD19、CD14、CD16、CD123モノクローナル抗体は、BD BiosciencesまたはBiolgendから購入した。
1~2×105濃縮DCを、96ウエルプレート、100μLの培地に播種し、100μLの希釈刺激薬をプレートに加え、37℃のインキュベーター中で20~22時間培養した。上清を採取し、ヒトIFN-α、IL-6、IL-12(p70)、及びTNF-αをELISA(Mabtech AB)により分析した。
全ての比較の有意性は、モックと試料群との間の不等分散を推定し、スチューデント両側t検定を使用して算出され、結果は、p<0.05の場合に有意であるとした。パラメーター間の相関関係は、スピアマンの順位相関検定を使用して評価し、P値<0.05を統計学的に有意であるとした。
患者由来胃癌腫異種移植片(PDX)マウスモデルの作製のため、6~8週齢の雌Balb/cヌードマウス(SLAC,中国上海から入手)を、腫瘍断片埋め込みに使用した。動物に、通常のヌードマウス食餌を与え、実験動物の管理と使用に関する指針(Guide for Care and Use of Laboratory Animals)、及び動物実験委員会(Institutional Animal Care and Use Committee)の規制に従って、SPF動物施設に収容した。大きさが約15~30mm3の特許STO番号69胃腫瘍断片をBalb/cヌードマウスの腹部右側(皮下)に埋め込んだ。
(付記1)
式(Ib):
TM-L-AM(Ib)
の構造を有する化合物であって、
式中、TMは標的部分であり、Lはリンカーであり、AMは式(I):
式中、破線は結合または結合の不在を表し、
Xは、Sまたは-NR1であり、R1は-W0―W1―W2―W3―W4であり、
W0は、結合、アルキル、アルケニル、アルキニル、アルコキシ、または-アルキル-S-アルキル--であり、
W1は、結合、--O--、または-NR2--であり、ここでR2は、水素、アルキルまたはアルケニルであり、
W2は、結合、--O--、--C(O)--、--C(S)--、または-S(O)2―であり、
W3は、結合、--NR3--であり、ここでR3は、水素、アルキルまたはアルケニルであり、
W4は、水素、アルキル、アルケニル、アルキニル、アルコキシ、シクロアルキル、アリール、アリールオキシ、ヘテロアリール、またはヘテロシクリルであり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、シクロアルキル、アリール、ヘテロアリール、ヘテロシクリル、--NH2、ニトロ、--アルキル-ヒドロキシル、--アルキル-アリール、--アルキル-ヘテロアリール、--アルキル-ヘテロシクリル、--O-R4、--O-アルキル-R4、--アルキル-O-R4、--C(O)-R4、--アルキル-C(O)-R4、--アルキル-C(O)-O-R4、--C(O)-O-R4、--S-R4、--S(O)2-R4、--NH-S(O)2-R4、--アルキル-S-R4、--アルキル-S(O)2-R4、--NHR4、--NR4R4、--NH-アルキル-R4、ハロゲン、--CN、--NO2、及び-SHからなる群より選択される1つまたは複数の置換基により任意選択的に置換され、ここでR4は独立して、水素、アルキル、アルケニル、--アルキル-ヒドロキシル、アリール、ヘテロアリール、ヘテロシクリル、またはハロアルキルであり;
Zは、水素、アルキル、アルケニル、アルキニル、アルコキシ、アリール、ハロアルキル、ヘテロアリール、ヘテロシクリルであり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、アリール、ヘテロアリール、ヘテロシクリル、ハロゲン、シアノ、ニトロ、--N(R5)2、--アルコキシ-アルキル、--アルコキシ-アルケニル、--C(O)-アルキル、--C(O)-O-アルキル、--O-C(O)-アルキル、--C(O)-N(R5)2、アリール、ヘテロアリール、--CO-アリール、及び-CO-ヘテロアリールからなる群より選択される1つまたは複数の置換基により任意選択的に置換されることができ、ここで各R5は独立して、水素、アルキル、ハロアルキル、--アルキル-アリール、または-アルキル-ヘテロアリールであり;
Rは、水素、アルキル、アルコキシ、ハロアルキル、ハロゲン、アリール、ヘテロアリール、ヘテロシクリルであり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、シクロアルキル、アリール、ヘテロアリール、ヘテロシクリル、--NH2、ニトロ、--アルキル-ヒドロキシル、--アルキル-アリール、--アルキル-ヘテロアリール、--アルキル-ヘテロシクリル、--O-R4、--O-アルキル-R4、--アルキル-O-R4、--C(O)-R4、--C(O)-NH-R4、--C(O)-NR4R4、--アルキル-C(O)-R4、--アルキル-C(O)-O-R4、--C(O)-O-R4、--O-C(O)-R4、--S-R4、--C(O)-S-R4、--S-C(O)-R4、--S(O)2-R4、--NH-S(O)2-R4、--アルキル-S-R4、--アルキル-S(O)2-R4、--NHR4、--NR4R4、--NH-アルキル-R4、ハロゲン、--CN、及び-SHからなる群より選択される1つまたは複数の置換基により任意選択的に置換され、ここでR4は独立して、水素、アルキル、アルケニル、アルコキシ、--アルキル-ヒドロキシル、アリール、ヘテロアリール、ヘテロシクリル、またはハロアルキルであり;
nは、0、1、2、3、または4であり;
Yは、-NR6R7、-CR6R7R8、または-アルキル-NH2であり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、--NH2、ハロゲン、--N(R5)2、--アルコキシ-アルキル、--アルコキシ-アルケニル、--C(O)-アルキル、--C(O)-O-アルキル、--C(O)-N(R5)2、アリール、ヘテロアリール、--CO-アリール、及び-CO-ヘテロアリールからなる群より選択される1つまたは複数の置換基により任意選択的に置換されることができ、
ここでR6、R7及びR8は独立して、水素、アルキル、アルケニル、アルコキシ、アルキルアミノ、ジアルキルアミノ、アルキルチオ、アリールチオ、--アルキル-ヒドロキシル、--アルキル-C(O)-O-R9、--アルキル-C(O)-R9、または-アルキル-O-C(O)-R9であり、ここで各R5は独立して、水素、アルキル、ハロアルキル、--アルキル-アリール、または-アルキル-ヘテロアリールであり、ここでR9は、水素、アルキル、アルケニル、ハロゲン、またはハロアルキルであり;
X及びZは一緒になって、任意選択的に(5~9)員環を形成し得る、
化合物、またはその薬学的に許容され得る塩もしくは溶媒和物。
Lが式(II):
mは、1、2、3、4、5、または6であり、各bは独立して、0または1であり、Dは独立して、式(III):
式中、各iは独立して、0または1であり;
各jは独立して、0、1、2、3、4、5、または6であり;
各Aは独立して、S、O、またはN-Raであり、ここでRaは、水素、アルキル、アルケニル、またはアルコキシであり;
各Bは独立して、アルキル、アルケニル、--O-アルキル-、--アルキル-O--、--S-アルキル--、--アルキル-S--、アリール、ヘテロアリール、ヘテロシクリル、またはペプチドであり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、シクロアルキル、--アルキル-アリール、--アルキル-ヘテロアリール、--アルキル-ヘテロシクリル、--O-R4、--O-アルキル-R4、--C(O)-R4、--C(O)-O-R4、--S-R4、--S(O)2-R4、--NHR4、--NH-アルキル-R4、ハロゲン、--CN、--NO2、及び-SHからなる群より選択される1つまたは複数の置換基により任意選択的に置換され、ここでR4は、アルキル、アルケニル、--アルキル-ヒドロキシル、アリール、ヘテロアリール、ヘテロシクリル、またはハロアルキルである、
付記1に記載の化合物。
Xが-NR1であり、R1がアルキル、--アルキル-W4、--アルキル-O-W4、--アルキル-NH-C(O)-W4、--アルコキシ-NH-C(O)-W4、--アルキル-NH-C(O)-NH-W4、--アルコキシ-NH-C(O)-NH-W4、--アルキル-S(O)2-W4、または--アルキル-NH-C(S)-W4である、付記1に記載の化合物。
XがSである、付記1に記載の化合物。
Zが、水素、アルキル、アルコキシ、アリール、ヘテロアリール、ハロアルキルであり、そのそれぞれがヒドロキシル、アルキル、アリール、ヘテロアリール、ヘテロシクリル、シアノ、--アルコキシ-アルキル、ニトロ、及び-N(R5)2からなる群より選択される1~3個の置換基により任意選択的に置換され、ここで各R5が独立して、水素、アルキル、ハロアルキル、--アルキル-アリール、または-アルキル-ヘテロアリールである、付記1~4のいずれか1つに記載の化合物。
nが1または2であり、Rがアリールまたはヘテロアリールであり、そのそれぞれが、ヒドロキシル、アルコキシ、--アルキル-ヒドロキシル、--O-R4、--O-アルキル-R4、--アルキル-O-R4、--C(O)-R4、--C(O)-NH-R4、--C(O)-NR4R4、--アルキル-C(O)-R4、--アルキル-C(O)-O-R4、--C(O)-O-R4、--O-C(O)-R4、--S-R4、--C(O)-S-R4、--S-C(O)-R4、--S(O)2-R4、--NH-S(O)2-R4、--アルキル-S-R4、--アルキル-S(O)2-R4、--NHR4、--NR4R4、--NH-アルキル-R4、ハロゲン、--CN、及び-SHからなる群より選択される1~3個の置換基により任意選択的に置換され、ここでR4が独立して、水素、アルキル、アルケニル、アルコキシ、--アルキル-ヒドロキシル、アリール、ヘテロアリール、ヘテロシクリル、またはハロアルキルである、付記1~5のいずれか1つに記載の化合物。
Yが-NH2、--アルキル-NH2であり、そのそれぞれが、アルキル、アルコキシ、アルケニル、及びアルキニルからなる群より選択される1~3個の置換基により任意選択的に置換される、付記1~6のいずれか1つに記載の化合物。
AMが、2-プロピルチアゾロ[4,5-c]キノリン-4-アミン、1-(2-メチルプロピル)-1H-イミダゾ[4,5-c]キノリン-4-アミン、4-アミノ-2-(エトキシメチル)-a,a-ジ-メチル-1H-イミダゾ[4,5-c]キノリン-1-エタノール、1-(4-アミノ-2-エチルアミノメチルイミダゾ-[4,5-c]キノリン-1-イル)-2-メチルプロパン-2-オール、N-[4-(4-アミノ-2-エチル-1H-イミダゾ[4,5-c]キノリン-1-イル)ブチル-]メタンスルホンアミド、4-アミノ-2-エトキシメチル-aa-ジメチル-6,7,8,9-テトラヒドロ-1H-イミダゾ[4,5-c]キノリン-1-エタノール、4-アミノ-aa-ジメチル-2-メトキシエチル-1H-イミダゾ[4,5-c]キノリン-1-エタノール、1-{2-[3-(ベンジルオキシ)プロポキシ]エチル}-2-(エトキシメチル)-1H-イミダゾ[4,5-c]キノリン-4-アミン、N-[4-(4-アミノ-2-ブチル-1H-イミダゾ[4,5-c][1,5]ナフチリジン-1-イル)ブチル]-n’-ブチル尿素、N1-[2-(4-アミノ-2-ブチル-1H-イミダゾ[4,5-c][1,5]ナフチリジン-1-イル)エチル]-2-アミノ-4-メチルペンタンアミド、N-(2-{2-[4-アミノ-2-(2-メトキシエチル)-1H-イミダゾ[4,5-c]キノリン-1-イル]エトキシ}エチル)-n’-フェニル尿素、1-(2-アミノ-2-メチルプロピル)-2-(エトキシメチル)-1H-イミダゾ[4,5-c]キノリン-4-アミン、1-{4-[(3,5-ジクロロフェニル)スルホニル]ブチル}-2-エチル-1H-イミダゾ[4,5-c]キノリン-4-アミン、N-(2-{2-[4-アミノ-2-(エトキシメチル)-1H-イミダゾ[4,5-c]キノリン-1-イル]エトキシ}エチル)-n’-シクロヘキシル尿素、N-{3-[4-アミノ-2-(エトキシメチル)-1H-イミダゾ[4,5-c]キノリン-1-イル]プロピル}-n’-(3-シアノフェニル)チオ尿素、N-[3-(4-アミノ-2-ブチル-1H-イミダゾ[4,5-c]キノリン-1-イル)-2,2-ジメチルプロピル]ベンズアミド、2-ブチル-1-[3-(メチルスルホニル)プロピル]-1H-イミダゾ[4,5-c]キノリン-4-アミン、N-{2-[4-アミノ-2-(エトキシメチル)-1H-イミダゾ[4,5-c]キノリン-1-イル]-1,1-ジメチルエチル}-2-エトキシアセトアミド、1-[4-アミノ-2-エトキシメチル-7-(ピリジン-4-イル)-1H-イミダゾ[4,5-c]キノリン-1-イル]-2-メチルプロパン-2-オール、1-[4-アミノ-2-(エトキシメチル)-7-(ピリジン-3-イル)-1H-イミダゾ[4,5-c]キノリン-1-イル]-2-メチルプロパン-2-オール、N-{3-[4-アミノ-1-(2-ヒドロキシ-2-メチルプロピル)-2-(メトキシエチル)-1H-イミダゾ[4,5-c]キノリン-7-イル]フェニル}メタンスルホンアミド、1-[4-アミノ-7-(5-ヒドロキシメチルピリジン-3-イル)-2-(2-メトキシエチル)-1H-イミダゾ[4,5-c]キノリン-1-イル]-2-メチルプロパン-2-オール、3-[4-アミノ-2-(エトキシメチル)-7-(ピリジン-3-イル)-1H-イミダゾ[4,5-c]キノリン-1-イル]プロパン-1,2-ジオール、1-[2-(4-アミノ-2-エトキシメチル-1H-イミダゾ[4,5-c]キノリン-1-イル)-1,1-ジメチルエチル]-3-プロピル尿素、1-[2-(4-アミノ-2-エトキシメチル-1H-イミダゾ[4,5-c]キノリン-1-イル)-1,1-ジメチルエチル]-3-シクロペンチル尿素、1-[(2,2-ジメチル-1,3-ジオキソラン-4-イル)メチル]-2-(エトキシメチル)-7-(4-ヒドロキシメチルフェニル)-1H-イミダゾ[4,5-c]キノリン-4-アミン、4-[4-アミノ-2-エトキシメチル-1-(2-ヒドロキシ-2-メチルプロピル)-1H-イミダゾ[4,5-c]キノリン-7-イル]-N-メトキシ-N-メチルベンズアミド、2-エトキシメチル-N1-イソプロピル-6,7,8,9-テトラヒドロ-1H-イミダゾ[4,5-c]キノリン-1,4-ジアミン、1-[4-アミノ-2-エチル-7-(ピリジン-4-イル)-1H-イミダゾ[4,5-c]キノリン-1-イル]-2-メチルプロパン-2-オール、N-[4-(4-アミノ-2-エチル-1H-イミダゾ[4,5-c]キノリン-1-イル)ブチル]メタンスルホンアミド、及びN-[4-(4-アミノ-2-ブチル-1H-イミダゾ[4,5-c][1,5]ナフチリジン-1-イル)ブチル]-n’-シクロヘキシル尿素からなる群より選択される化合物である、付記1に記載の化合物。
TMが、免疫グロブリン、タンパク質、小分子、ナノ粒子、または核酸を含む、付記1~9のいずれか1つに記載の化合物。
TMが、非腫瘍細胞と比較して特異的または優先的に腫瘍細胞に結合する、付記10に記載の化合物。
TMが、前記腫瘍細胞上の腫瘍抗原に特異的に結合する、付記11に記載の化合物。
前記腫瘍抗原が、CD2、CD19、CD20、CD22、CD27、CD33、CD37、CD38、CD40、CD44、CD47、CD52、CD56、CD70、CD79、CD137、4-1BB、5T4、AGS-5、AGS-16、アンジオポエチン2、B7.1、B7.2、B7DC、B7H1、B7H2、B7H3、BT-062、BTLA、CAIX、癌胎児性抗原、CTLA4、クリプト、ED-B、ErbB1、ErbB2、ErbB3、ErbB4、EGFL7、EpCAM、EphA2、EphA3、EphB2、FAP、フィブロネクチン、葉酸受容体、ガングリオシドGM3、GD2、グルココルチコイド誘発性腫瘍壊死因子受容体(GITR)、gp100、gpA33、GPNMB、ICOS、IGF1R、インテグリン(Integrin)、KIR、LAG-3、ルイスY、メソテリン、c-MET、MN炭酸脱水酵素IX、MUC1、MUC16、ネクチン-4、NKG2D、NOTCH、OX40、OX40L、PD-1、PDL1、PSCA、PSMA、RANKL、ROR1、ROR2、SLC44A4、シンデカン-1、TACI、TAG-72、テネイシン、TIM3、TRAILR1、TRAILR2、VEGFR-1、VEGFR-2、VEGFR-3、及びそれらの変異体からなる群より選択される、付記12に記載の化合物。
TMが、抗体またはその機能性断片を含む、付記10に記載の化合物。
TMが、Rituxan(リツキシマブ)、Herceptin(トラスツズマブ)、Erbitux(セツキシマブ)、Vectibix(パニツムマブ)、Arzerra(オファツムマブ)、Benlysta(ベリムマブ)、Yervoy(イピリムマブ)、Perjeta(ペルツズマブ)、トレメリムマブ、ニボルマブ、ダセツズマブ、ウレルマブ、MPDL3280A、ランブロリズマブ、ブリナツモマブ、アルデスロイキン;アレムツズマブ(aemtuzumab);アリトレチノイン;アロプリノール;アルトレタミン;アミフォスチン;アナストロゾール;三酸化ヒ素;アスパラギナーゼ;BCG生菌;ベキサロテンカプセル;ベキサロテンゲル;ブレオマイシン;静注用ブスルファン;経口用ブスルファン;カルステロン;カペシタビン;カルボプラチン;カルムスチン;ポリフェプロサン20インプラントを伴うカルムスチン;セレコキシブ;クロラムブシル;シスプラチン;クラドリビン;シクロホスファミド;シタラビン;シタラビンリポソーム;ダカルバジン;ダクチノマイシン;アクチノマイシンD;ダルベポエチンα(dabepoetin alfa);ダウノルビシンリポソーム;ダウノルビシン、ダウノマイシン;デニロイキンジフチトックス、デクスラゾキサン;ドセタキセル;ドキソルビシン;ドキソルビシンリポソーム;プロピオン酸ドロモスタノロン;エリオットB液;エピルビシン;エポエチン(eoetin)αエストラムスチン;リン酸エトポシド;エトポシド(VP-16);エキセメスタン;フィルグラスチム;フロクスウリジン(動注用);フルダラビン;フルオロウラシル(5-FU);フルベストラント;ゲムツズマブオゾガマイシン;ゴセレリン酢酸塩;ヒドロキシ尿素;イブリツモマブチウキセタン;イダルビシン;イホスファミド;イマチニブメシル酸塩;インターフェロンα-2a;インターフェロンα-2b;イリノテカン;レトロゾール;ロイコボリン;レバミゾール;ロムスチン(CCNU);メクロレタミン(ナイトロジェンマスタード);酢酸メゲストロール;メルファラン(L-PAM);メルカプトプリン(6-MP);メスナ;メトトレキセート;メトキサレン;マイトマイシンC;ミトタン;ミトキサントロン;ナンドロロンフェンプロピオナート;ノフェツモマブ(nfetumomab);LOddC;オプレルベキン(orelvekin);オキサリプラチン;パクリタキセル;パミドロネート;ペガデマーゼ;ペガスパルガーゼ;ペグフィルグラスチム;ペントスタチン;ピポブロマン;プリカマイシン;ミトラマイシン;ポルフィマーナトリウム;プロカルバジン;キナクリン;ラスブリカーゼ;サルグラモスチム;ストレプトゾシン;テルビブジン(talbuvidine)(LDT);タルク;タモキシフェン;テモゾロミド;テニポシド(VM-26);テストラクトン;チオグアニン(6-TG);チオテパ;トポテカン;トレミフェン;トシツモマブ;トレチノイン(ATRA);ウラシルマスタード;バルルビシン;バルトルシタビン(モノバルLDC);ビンブラスチン;ビノレルビン;ゾレドロネート;及びそれらの混合物を含む、付記10に記載の化合物。
有効量の付記1~15のいずれか1つに記載の化合物及び1つまたは複数の薬学的に許容され得る担体を含む、医薬組成物。
有効量の追加の治療剤をさらに含む、付記16に記載の医薬組成物。
前記追加の治療剤が抗癌剤である、付記17に記載の医薬組成物。
前記抗癌剤が、代謝拮抗薬、トポイソメラーゼI及びIIの阻害剤、アルキル化剤、微小管阻害剤、抗アンドロゲン剤、GNRhモジュレータまたはそれらの混合物である、付記17に記載の医薬組成物。
腫瘍細胞の増殖を阻害する方法であって、前記腫瘍細胞に付記1~15のいずれか1つに記載の化合物を投与することを含む、方法。
対象における疾患を処置する方法であって、前記対象に付記1~15のいずれか1つに記載の化合物を投与することを含む、方法。
前記疾患が、胃、結腸、直腸、肝臓、膵臓、肺、乳房、子宮頚部、子宮体部、卵巣、精巣、膀胱、腎臓部、脳/CNS、頭頸部、喉、ホジキン病、非ホジキンリンパ腫、多発性骨髄腫、白血病、黒色腫、非黒色腫皮膚癌、急性リンパ性白血病、急性骨髄性白血病、ユーイング肉腫、小細胞肺癌、絨毛癌、横紋筋肉腫、ウィルムス腫瘍、神経芽腫、有毛細胞白血病、口腔/咽頭、食道、喉頭またはリンパ腫から選択された癌である、付記21に記載の方法。
対象内の疾患を処置するための医薬品の製造における付記1~15のいずれか1つに記載の化合物の使用。
対象内の疾患を処置するための医薬品の製造における付記16~19のいずれか1つに記載の医薬組成物の使用。
式(Ib):
TM-L-AM(Ib)
の構造を有する化合物であって、
式中、TMは標的部分であり、Lはリンカーであり、AMは式(IV):
式中、
Vは、-NR6R7であり、R6及びR7のそれぞれは独立して、水素、アルキル、アルケニル、アルコキシ、アルキルアミノ、ジアルキルアミノ、アルキルチオ、アリールチオ、--アルキル-ヒドロキシル、--アルキル-C(O)-O-R9、--アルキル-C(O)-R9、または-アルキル-O-C(O)-R9であり、ここでR9は、水素、アルキル、アルケニル、ハロゲン、またはハロアルキルであり;
R10及びR11は独立して、水素、アルキル、アルケニル、アリール、ハロアルキル、ヘテロアリール、ヘテロシクリル、またはシクロアルキルであり、そのそれぞれは、ヒドロキシル、アルコキシ、アルキル、アルケニル、アルキニル、ハロゲン、--N(R5)2、--アルコキシ-アルキル、--アルコキシ-アルケニル、--C(O)-アルキル、--C(O)-O-アルキル、--C(O)-N(R5)2、アリール、ヘテロアリール、--CO-アリール、及び-CO-ヘテロアリールからなる群より選択される1つまたは複数の置換基により任意選択的に置換され、ここで各R5は独立して、水素、アルキル、ハロアルキル、--アルキル-アリール、または-アルキル-ヘテロアリールである、化合物、またはその薬学的に許容され得る塩もしくは溶媒和物。
有効量の付記25に記載の化合物及び1つまたは複数の薬学的に許容され得る担体を含む医薬組成物。
有効量の追加の治療剤をさらに含む、付記26に記載の医薬組成物。
Claims (13)
- 下記の式(Ib)の構造を有する化合物であって、
TM-L-AM (Ib)
前記化合物は、標的部分(TM)と、活性化部分(AM)と、前記標的部分及び前記活性化部分を接続するリンカー(L)とを含み、
前記活性化部分は、下記の式(II)の構造により表される活性化部分であり、
(式中、破線は結合または結合の不在を表し、
R 1 は、2-メチルプロパン-2-オールであり、
Zは、エトキシメチルであり、
Rは、水素であり、
nは、4である。)
前記標的部分は、Her2またはEGFRに特異的に結合する免疫グロブリンを含む、
化合物、またはその薬学的に許容され得る塩もしくは溶媒和物。 - 前記免疫グロブリンが、抗体またはその機能性断片を含む、請求項1に記載の化合物またはその薬学的に許容され得る塩もしくは溶媒和物。
- 前記標的部分は、治療モノクローナル抗体を含む、請求項1または2に記載の化合物またはその薬学的に許容され得る塩もしくは溶媒和物。
- 前記免疫グロブリンが、Herceptin(トラスツズマブ)、Erbitux(セツキシマブ)、Vectibix(パニツムマブ)、Perjeta(ペルツズマブ)、これらの機能的断片、またはそれらの混合物を含む、請求項1から3のいずれか1項に記載の化合物またはその薬学的に許容され得る塩もしくは溶媒和物。
- 前記免疫グロブリンが、Her2に特異的に結合する、請求項1から4のいずれか1項に記載の化合物またはその薬学的に許容され得る塩もしくは溶媒和物。
- 前記免疫グロブリンが、EGFRに特異的に結合する、請求項1から4のいずれか1項に記載の化合物またはその薬学的に許容され得る塩もしくは溶媒和物。
- 前記免疫グロブリンが、細胞成長または増殖を阻害し得る、請求項1から3のいずれか1項に記載の化合物またはその薬学的に許容され得る塩もしくは溶媒和物。
- 前記免疫グロブリンが、直接または間接的にアポトーシスを誘発し得る、請求項1から3のいずれか1項に記載の化合物またはその薬学的に許容され得る塩もしくは溶媒和物。
- 有効量の請求項1から8のいずれか1項に記載の化合物またはその薬学的に許容され得る塩もしくは溶媒和物と、1つまたは複数の薬学的に許容され得る担体とを含む、医薬組成物。
- 有効量の追加の治療剤をさらに含む、請求項9に記載の医薬組成物。
- 前記追加の治療剤が、代謝拮抗薬、トポイソメラーゼI及びIIの阻害剤、アルキル化剤、微小管阻害剤、抗アンドロゲン剤、GNRhモジュレータ、及びそれらの混合物からなる群より選択される抗癌剤である、請求項10に記載の医薬組成物。
- 有効量の請求項5に記載の化合物またはその薬学的に許容され得る塩もしくは溶媒和物を含む、乳癌または胃癌の治療で用いるための、医薬組成物。
- 有効量の請求項6に記載の化合物またはその薬学的に許容され得る塩もしくは溶媒和物を含む、結腸直腸癌または頭頸部癌の治療で用いるための、医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022107558A JP2022126880A (ja) | 2014-01-10 | 2022-07-04 | 免疫療法のための化合物及び組成物 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410011262.8A CN104861063A (zh) | 2014-01-10 | 2014-01-10 | 靶向her2阳性肿瘤的化合物和组合物 |
CN201410011362.0 | 2014-01-10 | ||
CN201410011262.8 | 2014-01-10 | ||
CN201410011324.5 | 2014-01-10 | ||
CN201410011324.5A CN104861067A (zh) | 2014-01-10 | 2014-01-10 | 用于免疫疗法的化合物和组合物 |
CN201410011362.0A CN104861064A (zh) | 2014-01-10 | 2014-01-10 | 靶向表达egfr的肿瘤的化合物和组合物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016545803A Division JP6957154B2 (ja) | 2014-01-10 | 2015-01-08 | 免疫療法のための化合物及び組成物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022107558A Division JP2022126880A (ja) | 2014-01-10 | 2022-07-04 | 免疫療法のための化合物及び組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020114836A JP2020114836A (ja) | 2020-07-30 |
JP2020114836A5 JP2020114836A5 (ja) | 2021-02-12 |
JP7290332B2 true JP7290332B2 (ja) | 2023-06-13 |
Family
ID=53523554
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016545803A Active JP6957154B2 (ja) | 2014-01-10 | 2015-01-08 | 免疫療法のための化合物及び組成物 |
JP2016545882A Withdrawn JP2017502068A (ja) | 2014-01-10 | 2015-01-08 | Her2陽性腫瘍を処置するための化合物及び組成物 |
JP2016545802A Withdrawn JP2017503803A (ja) | 2014-01-10 | 2015-01-08 | Egfr発現腫瘍を処置するための化合物及び組成物 |
JP2020048941A Active JP7290332B2 (ja) | 2014-01-10 | 2020-03-19 | 免疫療法のための化合物及び組成物 |
JP2022107558A Pending JP2022126880A (ja) | 2014-01-10 | 2022-07-04 | 免疫療法のための化合物及び組成物 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016545803A Active JP6957154B2 (ja) | 2014-01-10 | 2015-01-08 | 免疫療法のための化合物及び組成物 |
JP2016545882A Withdrawn JP2017502068A (ja) | 2014-01-10 | 2015-01-08 | Her2陽性腫瘍を処置するための化合物及び組成物 |
JP2016545802A Withdrawn JP2017503803A (ja) | 2014-01-10 | 2015-01-08 | Egfr発現腫瘍を処置するための化合物及び組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022107558A Pending JP2022126880A (ja) | 2014-01-10 | 2022-07-04 | 免疫療法のための化合物及び組成物 |
Country Status (12)
Country | Link |
---|---|
US (11) | US9827329B2 (ja) |
EP (4) | EP3092256B1 (ja) |
JP (5) | JP6957154B2 (ja) |
CN (6) | CN105899537A (ja) |
AU (3) | AU2015205753A1 (ja) |
CA (3) | CA2936375A1 (ja) |
DK (1) | DK3092256T3 (ja) |
ES (1) | ES2916873T3 (ja) |
IL (3) | IL246680A0 (ja) |
SG (3) | SG11201605296SA (ja) |
TW (3) | TWI691337B (ja) |
WO (3) | WO2015103989A1 (ja) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
AU2015205753A1 (en) | 2014-01-10 | 2016-07-21 | Birdie Biopharmaceuticals Inc. | Compounds and compositions for treating HER2 positive tumors |
JP6760919B2 (ja) | 2014-07-09 | 2020-09-23 | バーディー バイオファーマシューティカルズ インコーポレイテッド | 腫瘍を治療するための抗pd−l1組み合わせ |
CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
CN108137586B (zh) | 2015-09-14 | 2021-04-13 | 辉瑞大药厂 | 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物 |
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
CA3007311A1 (en) * | 2015-12-07 | 2017-06-15 | Opi Vi - Ip Holdco Llc | Compositions of antibody construct-agonist conjugates and methods of use thereof |
CN115350279A (zh) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-cd20组合 |
TWI825834B (zh) | 2016-03-02 | 2023-12-11 | 日商衛材R&D企管股份有限公司 | 基於艾日布林之抗體-藥物結合物及使用方法 |
CN115317603A (zh) | 2016-07-07 | 2022-11-11 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
CN107773762B (zh) * | 2016-08-31 | 2021-06-15 | 上海干云生物科技有限公司 | 基于pd-l1抗体偶联化疗药物的adc及其制备方法和应用 |
RU2766586C2 (ru) | 2016-10-28 | 2022-03-15 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или предупреждения злокачественной опухоли |
CA3042583A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
AU2017376460A1 (en) * | 2016-12-13 | 2019-06-20 | Bolt Biotherapeutics, Inc. | Antibody adjuvant conjugates |
DK3609540T5 (da) * | 2017-04-14 | 2024-09-02 | Bolt Biotherapeutics Inc | Fremgangsmåde til immunkonjugatsyntese |
CN118515666A (zh) | 2017-04-27 | 2024-08-20 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
EP3641771A4 (en) * | 2017-06-23 | 2020-12-16 | Birdie Biopharmaceuticals, Inc. | PHARMACEUTICAL COMPOSITIONS |
WO2019008441A1 (en) | 2017-07-04 | 2019-01-10 | Intocell, Inc. | COMPOUNDS COMPRISING A CLIABABLE BIT AND USES THEREOF |
US10618896B2 (en) | 2017-08-22 | 2020-04-14 | Dynavax Technologies Corporation | Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof |
CA3080640C (en) | 2017-11-06 | 2024-04-09 | Trillium Therapeutics Inc. | Cd47 blockade with radiation therapy |
US10722591B2 (en) | 2017-11-14 | 2020-07-28 | Dynavax Technologies Corporation | Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof |
KR102436923B1 (ko) * | 2018-01-26 | 2022-08-26 | 주식회사 엘지화학 | 광 감응기를 포함하는 블록 공중합체 |
CN111801315A (zh) * | 2018-03-03 | 2020-10-20 | 国立大学法人东京大学 | 利用癌特异性酶活性的前药型抗癌剂 |
WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
TWI672637B (zh) * | 2018-05-03 | 2019-09-21 | 長庚醫療財團法人林口長庚紀念醫院 | 自體免疫抗體免疫螢光影像型態識別方法 |
CN109134654B (zh) * | 2018-08-02 | 2021-08-03 | 广东药科大学 | 一种靶向egfr二聚化界面的单链抗体及其应用 |
FR3085952B1 (fr) * | 2018-09-17 | 2020-10-30 | Centre Nat Rech Scient | Conjugue anticorps-medicament comprenant des derives de quinoline |
WO2020141460A2 (en) * | 2019-01-03 | 2020-07-09 | Intocell, Inc. | Compounds comprising cleavable linker and uses thereof |
CN113453726A (zh) * | 2019-01-03 | 2021-09-28 | 尹图赛利有限公司 | 包含可裂解接头的化合物及其用途 |
KR20210136014A (ko) * | 2019-02-12 | 2021-11-16 | 암브룩스, 인코포레이티드 | 항체-tlr 작용제 콘쥬게이트를 함유하는 조성물, 방법 및 이의 용도 |
CN113993549A (zh) | 2019-03-15 | 2022-01-28 | 博尔特生物治疗药物有限公司 | 靶向her2的免疫缀合物 |
EP4106819A1 (en) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
WO2022006327A1 (en) | 2020-07-01 | 2022-01-06 | Silverback Therapeutics, Inc. | Anti-asgr1 antibody conjugates and uses thereof |
CA3192776A1 (en) * | 2020-08-26 | 2022-03-03 | Lixin Li | Cancer treatment with tlr agonist |
EP4211171A2 (en) | 2020-09-10 | 2023-07-19 | Precirix N.V. | Antibody fragment against fap |
US20230373997A1 (en) * | 2020-10-08 | 2023-11-23 | Icahn School Of Medicine At Mount Sinai | Imdq-peg-chol adjuvant and uses thereof |
IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Preparations containing an antibody against HER2/NEU and their use |
WO2022120014A1 (en) * | 2020-12-04 | 2022-06-09 | Macrogenics, Inc. | Pharmaceutical compositions of a her2/neu antibody and use of the same |
CN117355341A (zh) * | 2021-03-02 | 2024-01-05 | 纽约州立大学研究基金会 | 用于治疗癌症和/或感染性疾病的tlr7和tlr8激动剂 |
CN117813112A (zh) | 2021-08-30 | 2024-04-02 | 东丽株式会社 | 免疫原性增强用组合物 |
CN117813113A (zh) | 2021-08-30 | 2024-04-02 | 东丽株式会社 | 免疫原性增强用组合物 |
EP4403182A1 (en) | 2021-09-16 | 2024-07-24 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
EP4429654A1 (en) | 2021-11-09 | 2024-09-18 | Case Western Reserve University | Psma targeted conjugate compounds and uses thereof |
WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
WO2024118785A2 (en) | 2022-11-30 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Tlr7 agonists and antibody-drug-conjugates thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008531580A (ja) | 2000-12-08 | 2008-08-14 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答修飾因子の標的化送達のための組成物および方法 |
JP2008531590A (ja) | 2005-02-24 | 2008-08-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | カリウムイオンチャンネル開口薬としての新規なキノリン誘導体 |
JP2010523469A (ja) | 2007-03-30 | 2010-07-15 | ジェネンテック, インコーポレイテッド | 抗体及びイムノコンジュゲートとこれらの使用方法 |
JP6957154B2 (ja) | 2014-01-10 | 2021-11-02 | バーディー バイオファーマシューティカルズ インコーポレイテッド | 免疫療法のための化合物及び組成物 |
Family Cites Families (179)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
CA1271477A (en) | 1983-11-18 | 1990-07-10 | John F. Gerster | 1h-imidazo[4,5-c]quinolin-4-amines |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Noble hydrazonic history of anthracycline and methods for their preparation |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US6399754B1 (en) | 1991-12-24 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides |
US6005087A (en) | 1995-06-06 | 1999-12-21 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US6716580B2 (en) | 1990-06-11 | 2004-04-06 | Somalogic, Inc. | Method for the automated generation of nucleic acid ligands |
US5874218A (en) | 1990-06-11 | 1999-02-23 | Nexstar Pharmaceuticals, Inc. | Method for detecting a target compound in a substance using a nucleic acid ligand |
US6465189B1 (en) | 1990-06-11 | 2002-10-15 | Gilead Sciences, Inc. | Systematic evolution of ligands by exponential enrichment: blended selex |
US6280932B1 (en) | 1990-06-11 | 2001-08-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands to lectins |
US5763177A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
US5853984A (en) | 1990-06-11 | 1998-12-29 | Nexstar Pharmaceuticals, Inc. | Use of nucleic acid ligands in flow cytometry |
US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
US5789163A (en) | 1990-06-11 | 1998-08-04 | Nexstar Pharmaceuticals, Inc. | Enzyme linked oligonucleotide assays (ELONAS) |
US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
US6001577A (en) | 1998-06-08 | 1999-12-14 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
US5475096A (en) | 1990-06-11 | 1995-12-12 | University Research Corporation | Nucleic acid ligands |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
US5226575A (en) | 1991-11-21 | 1993-07-13 | Scott Faust | Pneumatic mortar dispenser with flex release |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
US6608201B2 (en) | 1992-08-28 | 2003-08-19 | 3M Innovative Properties Company | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
US6458539B1 (en) | 1993-09-17 | 2002-10-01 | Somalogic, Inc. | Photoselection of nucleic acid ligands |
US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5843732A (en) | 1995-06-06 | 1998-12-01 | Nexstar Pharmaceuticals, Inc. | Method and apparatus for determining consensus secondary structures for nucleic acid sequences |
ATE234635T1 (de) | 1995-12-22 | 2003-04-15 | Bristol Myers Squibb Co | Verzweigte hydrazongruppen enthaltende kuppler |
US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
JP2001504448A (ja) | 1996-08-30 | 2001-04-03 | フュルステ,イェンス,ペーター | 核酸の鏡面対称選択および進化 |
US6127533A (en) | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
UA67760C2 (uk) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
US6242246B1 (en) | 1997-12-15 | 2001-06-05 | Somalogic, Inc. | Nucleic acid ligand diagnostic Biochip |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
US6403779B1 (en) | 1999-01-08 | 2002-06-11 | Isis Pharmaceuticals, Inc. | Regioselective synthesis of 2′-O-modified nucleosides |
US20030054360A1 (en) | 1999-01-19 | 2003-03-20 | Larry Gold | Method and apparatus for the automated generation of nucleic acid ligands |
CA2370466C (en) | 1999-06-25 | 2011-02-08 | Sharon Erickson | Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
US6451810B1 (en) | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6506887B1 (en) | 1999-07-29 | 2003-01-14 | Somalogic, Incorporated | Conditional-selex |
US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
US6376669B1 (en) | 1999-11-05 | 2002-04-23 | 3M Innovative Properties Company | Dye labeled imidazoquinoline compounds |
US20050020525A1 (en) | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
US20050032733A1 (en) | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
DE20014503U1 (de) | 2000-08-22 | 2001-01-11 | Siemens AG, 80333 München | Fertigungsstraßenabschnitt |
US6376190B1 (en) | 2000-09-22 | 2002-04-23 | Somalogic, Inc. | Modified SELEX processes without purified protein |
US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
UA74593C2 (en) | 2000-12-08 | 2006-01-16 | 3M Innovative Properties Co | Substituted imidazopyridines |
US20060057651A1 (en) | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US20030175950A1 (en) | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
ATE452655T1 (de) | 2001-06-10 | 2010-01-15 | Noxxon Pharma Ag | Verwendung von l-polynukleotiden zur diagnostischen bilderzeugung |
AU2775402A (en) | 2001-06-29 | 2003-01-02 | Medimolecular Pty Ltd | Nucleic acid ligands to complex targets |
JP2005519990A (ja) | 2001-10-12 | 2005-07-07 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物 |
ATE416771T1 (de) | 2001-11-16 | 2008-12-15 | 3M Innovative Properties Co | N-ä4-(4-amino-2-ethyl-1h-imidazoä4,5-cüchinolin 1-yl)butylümethanesulfonamide, diese enthaltende pharmazeutische zusammensetzung und deren verwendung |
NZ533628A (en) | 2001-11-27 | 2006-07-28 | Anadys Pharmaceuticals Inc | 3-beta-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and uses thereof |
US7157452B2 (en) | 2001-12-31 | 2007-01-02 | Mgi Gp, Inc. | Substituted 4,9-dihydrocyclopenta{imn}phenanthridine-5-ones derivatives thereof and their uses |
IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
WO2003105780A2 (en) | 2002-06-18 | 2003-12-24 | Epigenesis Pharmaceuticals, Inc. | A dry powder oligonucleotide formulation, preparation and its uses |
DK2206517T3 (da) | 2002-07-03 | 2023-11-06 | Ono Pharmaceutical Co | Immunpotentierende sammensætninger omfattende af anti-PD-L1-antistoffer |
EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
EP1413316A1 (en) | 2002-09-27 | 2004-04-28 | Bruno Robert | Bifunctional conjugates or fusion proteins |
NZ540826A (en) | 2002-12-20 | 2008-07-31 | 3M Innovative Properties Co | Aryl / hetaryl substituted imidazoquinolines |
CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
WO2004062603A2 (en) | 2003-01-09 | 2004-07-29 | Arizeke Pharmaceuticals Inc. | Methods of treating lung diseases |
US9259459B2 (en) | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
US7375180B2 (en) | 2003-02-13 | 2008-05-20 | 3M Innovative Properties Company | Methods and compositions related to IRM compounds and Toll-like receptor 8 |
JP5356648B2 (ja) | 2003-02-20 | 2013-12-04 | シアトル ジェネティックス, インコーポレイテッド | 抗cd70抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用 |
EA200600540A1 (ru) | 2003-09-05 | 2006-08-25 | Анадис Фармасьютикалз, Инк. | Введение лигандов tlr7 и их пролекарств для лечения инфекции вируса гепатита с |
WO2005079195A2 (en) | 2003-10-03 | 2005-09-01 | 3M Innovative Properties Company | Pyrazolopyridines and analogs thereof |
EP1673087B1 (en) | 2003-10-03 | 2015-05-13 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
RU2426734C2 (ru) | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Пиразолопиридины и их аналоги |
AU2004280143A1 (en) | 2003-10-11 | 2005-04-21 | Tekmira Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
ITMI20032121A1 (it) | 2003-11-04 | 2005-05-05 | Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm | Procedimento per la preparazione di imiquimod e suoi intermedi |
ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
JP2007517055A (ja) | 2003-12-30 | 2007-06-28 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答の増強 |
WO2005092893A1 (ja) | 2004-03-26 | 2005-10-06 | Dainippon Sumitomo Pharma Co., Ltd. | 9置換−8−オキソアデニン化合物 |
WO2006134423A2 (en) | 2004-07-18 | 2006-12-21 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
EP3088004B1 (en) * | 2004-09-23 | 2018-03-28 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
EP1809671B1 (en) | 2004-11-09 | 2014-07-16 | University Of Southern California | CpG/antibody conjugate against cancer |
EP1830876B1 (en) * | 2004-12-30 | 2015-04-08 | Meda AB | Use of imiquimod for the treatment of cutaneous metastases derived from a breast cancer tumor |
CN101155932A (zh) | 2005-04-14 | 2008-04-02 | 默克专利有限公司 | 基于在肿瘤组织中增加的egfr基因拷贝数的抗egfr抗体治疗 |
JP5122441B2 (ja) | 2005-04-19 | 2013-01-16 | シアトル ジェネティックス, インコーポレイテッド | ヒト化抗cd70結合剤およびその使用 |
JP5185813B2 (ja) | 2005-04-26 | 2013-04-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 癌免疫治療のための組成物および方法 |
JP2008540363A (ja) | 2005-05-04 | 2008-11-20 | ノクソン・フアルマ・アクチエンゲゼルシヤフト | シュピーゲルマーの新規な使用 |
EP2161336B2 (en) * | 2005-05-09 | 2017-03-29 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯 |
TW201402124A (zh) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯 |
KR20080080482A (ko) | 2005-09-07 | 2008-09-04 | 메디뮨 엘엘씨 | 독소가 컨쥬게이트된 eph 수용체 항체 |
ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
ES2416136T3 (es) * | 2005-09-26 | 2013-07-30 | Medarex, Inc. | Conjugados de anticuerpo-fármaco y su uso |
US8951528B2 (en) | 2006-02-22 | 2015-02-10 | 3M Innovative Properties Company | Immune response modifier conjugates |
WO2007103048A2 (en) | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
US20080031887A1 (en) | 2006-06-30 | 2008-02-07 | Joseph Lustgarten | Conjugates for inducing targeted immune responses and methods of making and using same |
US8138172B2 (en) | 2006-07-05 | 2012-03-20 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of TLR7 |
KR20140116546A (ko) | 2006-10-27 | 2014-10-02 | 제넨테크, 인크. | 항체 및 면역접합체 및 이들의 용도 |
EP2125779B1 (en) | 2006-12-21 | 2016-04-27 | F. Hoffmann-La Roche AG | Polymorphs of a mglur5 receptor antagonist |
US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
TWI422594B (zh) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體(dc-asgpr)接合抗原呈現細胞之藥劑 |
EA019151B1 (ru) | 2007-02-07 | 2014-01-30 | Дзе Регентс Оф Дзе Юниверсити Оф Калифорния | Конъюгаты синтетических агонистов tlr и их применение |
DK2155743T3 (da) | 2007-05-08 | 2012-11-05 | Astrazeneca Ab | Imidazoquinoliner med immunmodulerende egenskaber |
EP2178896A1 (en) | 2007-07-31 | 2010-04-28 | The Johns Hopkins University | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
WO2009025846A2 (en) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
ES2632052T3 (es) | 2007-09-28 | 2017-09-08 | Pfizer Inc. | Direccionamiento a células de cáncer usando nanopartículas |
WO2009089900A1 (en) | 2008-01-15 | 2009-07-23 | Meda Ab | Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives |
WO2009093250A2 (en) | 2008-01-25 | 2009-07-30 | Gavish-Galilee Bio Applications Ltd | Targeting of innate immune response to tumor site |
WO2009099650A2 (en) * | 2008-02-07 | 2009-08-13 | Carson Dennis A | Treatment of bladder diseases with a tlr7 activator |
AR070865A1 (es) | 2008-03-18 | 2010-05-12 | Genentech Inc | Combinaciones de un conjugado anticuerpo- farmaco anti- her2 y agentes quimioterapeuticos y los metodos de uso |
US8772243B2 (en) | 2008-08-20 | 2014-07-08 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for predicting the response to anti-cancer treatment with an agonist of TLR7 or an agonist of TLR8 |
CA2998281C (en) | 2008-09-26 | 2022-08-16 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1 antobodies and uses therefor |
US8895702B2 (en) | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
TWI557117B (zh) | 2008-12-09 | 2016-11-11 | 吉李德科學股份有限公司 | 用於製備可用作類鐸受體調節劑之化合物的中間體化合物 |
CN106995495A (zh) | 2009-01-12 | 2017-08-01 | 希托马克斯医疗有限责任公司 | 修饰抗体组合物及其制备和使用方法 |
PL2427485T3 (pl) | 2009-05-07 | 2017-10-31 | Immunocellular Therapeutics Ltd | Epitopy CD133 |
WO2010132622A2 (en) | 2009-05-14 | 2010-11-18 | The Regents Of The University Of California | Anticd20-cpg conjugates and methods of treating b cell malignancies |
US20110077263A1 (en) | 2009-09-29 | 2011-03-31 | University Of Southern California | Methods and Compositions of Toll-Like Receptor (TLR) Agonists |
KR101740171B1 (ko) | 2009-11-24 | 2017-05-25 | 메디뮨 리미티드 | B7―h1에 대한 표적화된 결합 물질 |
WO2011084726A1 (en) | 2009-12-21 | 2011-07-14 | 3M Innovative Properties Company | BIS [4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM] 4-[(3-CARBOXYLATO-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS |
WO2011084725A1 (en) | 2009-12-21 | 2011-07-14 | 3M Innovative Properties Company | 4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS |
EA024701B1 (ru) | 2010-04-13 | 2016-10-31 | Селлдекс Терапьютикс Инк. | Антитела, связывающие cd27 человека, и их применение |
WO2011150264A2 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Synthetic nanocarrier combination vaccines |
US20120039916A1 (en) | 2010-08-13 | 2012-02-16 | Baylor Research Institute | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
SG10201601089UA (en) | 2010-10-01 | 2016-03-30 | Ventirx Pharmaceuticals Inc | Therapeutic Use Of A TLR Agonist And Combination Therapy |
CN103476407A (zh) | 2010-12-09 | 2013-12-25 | 霍夫曼-拉罗奇有限公司 | 用帕利他赛和曲妥珠单抗-mcc-dm1治疗her2阳性癌症 |
CN103562201B (zh) | 2011-01-12 | 2016-10-19 | 帆德制药股份有限公司 | 作为toll样受体调节剂的取代的苯并氮杂卓 |
WO2012104344A1 (en) | 2011-02-01 | 2012-08-09 | Genmab A/S | Human antibodies and antibody-drug conjugates against cd74 |
TW201247706A (en) | 2011-03-08 | 2012-12-01 | Baylor Res Inst | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン,エルエルシー | B7−h1およびpd−1に結合する抗体およびその他の分子 |
US9499535B2 (en) | 2011-04-21 | 2016-11-22 | Origenis Gmbh | Kinase inhibitors |
AR086196A1 (es) | 2011-04-21 | 2013-11-27 | Origenis Gmbh | Derivados de pirazolo[3,4-c]quinolina, inhibidores de quinasa |
US8728486B2 (en) | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
LT2734551T (lt) | 2011-07-24 | 2018-04-10 | Cure Tech Ltd. | Humanizuotų imunomoduliuojančių monokloninių antikūnų variantai |
WO2013019906A1 (en) | 2011-08-01 | 2013-02-07 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
KR101899801B1 (ko) | 2011-08-11 | 2018-09-20 | 헌츠만 어드밴스드 머티리얼스 아메리카스 엘엘씨 | 벤족사진 화합물의 제조 방법 |
JP2014527983A (ja) | 2011-09-19 | 2014-10-23 | ザ ジョンズ ホプキンス ユニバーシティー | 癌免疫療法 |
WO2013063275A1 (en) | 2011-10-25 | 2013-05-02 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
CN104661683A (zh) | 2011-11-09 | 2015-05-27 | 埃森德生物制药有限公司 | 免疫调节缀合物 |
US9556167B2 (en) | 2012-05-02 | 2017-01-31 | Yale University | TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs) |
US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
JP6403166B2 (ja) | 2012-08-03 | 2018-10-10 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | 単一抗原抗pd−l1およびpd−l2二重結合抗体およびその使用方法 |
AR092219A1 (es) | 2012-08-23 | 2015-04-08 | Seattle Genetics Inc | Conjugados anticuerpo-farmaco (adc) que se unen a proteinas 158p1d7 |
US9637491B2 (en) | 2012-10-19 | 2017-05-02 | Origenis Gmbh | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors |
WO2014060113A1 (en) | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Novel kinase inhibitors |
EP2787005A1 (en) | 2013-04-02 | 2014-10-08 | Activartis Biotech GmbH | Targeted cancer immune therapy |
KR20160101073A (ko) | 2013-12-20 | 2016-08-24 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
CA2953507A1 (en) | 2014-06-25 | 2015-12-30 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
JP6760919B2 (ja) | 2014-07-09 | 2020-09-23 | バーディー バイオファーマシューティカルズ インコーポレイテッド | 腫瘍を治療するための抗pd−l1組み合わせ |
CN112546231A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
CN105732635A (zh) | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
MY191938A (en) | 2015-09-01 | 2022-07-19 | Taiho Pharmaceutical Co Ltd | Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof |
US10821127B2 (en) | 2015-11-09 | 2020-11-03 | Shaperon Inc. | Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient |
CN115350279A (zh) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-cd20组合 |
CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
CN118515666A (zh) | 2017-04-27 | 2024-08-20 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
EP3641771A4 (en) | 2017-06-23 | 2020-12-16 | Birdie Biopharmaceuticals, Inc. | PHARMACEUTICAL COMPOSITIONS |
WO2020051356A1 (en) | 2018-09-07 | 2020-03-12 | Birdie Biopharmaceuticals, Inc. | Imidazoquinoline compounds and uses thereof |
CN113613641A (zh) | 2018-12-26 | 2021-11-05 | 博笛生物科技有限公司 | 用于治疗癌症的免疫调节组合和方法 |
WO2020190690A1 (en) | 2019-03-15 | 2020-09-24 | Birdie Biopharmaceuticals, Inc. | Immune modulatory compositions and methods for treating cancers |
CA3192776A1 (en) | 2020-08-26 | 2022-03-03 | Lixin Li | Cancer treatment with tlr agonist |
-
2015
- 2015-01-08 AU AU2015205753A patent/AU2015205753A1/en not_active Abandoned
- 2015-01-08 EP EP15734849.1A patent/EP3092256B1/en active Active
- 2015-01-08 SG SG11201605296SA patent/SG11201605296SA/en unknown
- 2015-01-08 US US15/110,685 patent/US9827329B2/en active Active
- 2015-01-08 WO PCT/CN2015/070379 patent/WO2015103989A1/en active Application Filing
- 2015-01-08 AU AU2015205755A patent/AU2015205755C1/en not_active Ceased
- 2015-01-08 AU AU2015205756A patent/AU2015205756A1/en not_active Abandoned
- 2015-01-08 CA CA2936375A patent/CA2936375A1/en not_active Abandoned
- 2015-01-08 ES ES15734849T patent/ES2916873T3/es active Active
- 2015-01-08 CN CN201580004156.XA patent/CN105899537A/zh active Pending
- 2015-01-08 SG SG11201605449YA patent/SG11201605449YA/en unknown
- 2015-01-08 DK DK15734849.1T patent/DK3092256T3/da active
- 2015-01-08 CA CA2936376A patent/CA2936376A1/en active Pending
- 2015-01-08 US US15/110,690 patent/US10548985B2/en active Active
- 2015-01-08 EP EP15735122.2A patent/EP3092254A4/en active Pending
- 2015-01-08 CN CN201580004171.4A patent/CN105899538A/zh active Pending
- 2015-01-08 EP EP15735519.9A patent/EP3092255A4/en active Pending
- 2015-01-08 JP JP2016545803A patent/JP6957154B2/ja active Active
- 2015-01-08 WO PCT/CN2015/070380 patent/WO2015103990A1/en active Application Filing
- 2015-01-08 SG SG11201605455YA patent/SG11201605455YA/en unknown
- 2015-01-08 CN CN201580004172.9A patent/CN105899539B/zh active Active
- 2015-01-08 EP EP22167502.8A patent/EP4056594A1/en active Pending
- 2015-01-08 CA CA2936377A patent/CA2936377A1/en not_active Abandoned
- 2015-01-08 WO PCT/CN2015/070377 patent/WO2015103987A1/en active Application Filing
- 2015-01-08 JP JP2016545882A patent/JP2017502068A/ja not_active Withdrawn
- 2015-01-08 JP JP2016545802A patent/JP2017503803A/ja not_active Withdrawn
- 2015-01-08 CN CN202210215606.1A patent/CN114716555A/zh active Pending
- 2015-01-08 US US15/110,679 patent/US20170028079A1/en not_active Abandoned
- 2015-01-08 CN CN202210258366.3A patent/CN114671954A/zh active Pending
- 2015-01-08 CN CN202110943239.2A patent/CN113633783A/zh active Pending
- 2015-01-09 TW TW104100852A patent/TWI691337B/zh active
- 2015-01-09 TW TW104100853A patent/TWI691338B/zh active
- 2015-01-09 TW TW104100854A patent/TWI674904B/zh active
-
2016
- 2016-07-10 IL IL246680A patent/IL246680A0/en unknown
- 2016-07-10 IL IL246679A patent/IL246679A0/en unknown
- 2016-07-10 IL IL246681A patent/IL246681A0/en unknown
-
2017
- 2017-10-25 US US15/793,820 patent/US10328158B2/en active Active
-
2019
- 2019-05-02 US US16/401,797 patent/US10780180B2/en not_active Expired - Fee Related
- 2019-05-02 US US16/401,834 patent/US10744206B2/en not_active Expired - Fee Related
- 2019-12-12 US US16/711,652 patent/US20200155700A1/en not_active Abandoned
-
2020
- 2020-03-19 JP JP2020048941A patent/JP7290332B2/ja active Active
- 2020-05-19 US US16/878,010 patent/US11786604B2/en active Active
- 2020-07-21 US US16/934,803 patent/US11633494B2/en active Active
- 2020-07-28 US US16/940,697 patent/US11633495B2/en active Active
-
2022
- 2022-07-04 JP JP2022107558A patent/JP2022126880A/ja active Pending
-
2023
- 2023-04-17 US US18/135,607 patent/US20230390410A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008531580A (ja) | 2000-12-08 | 2008-08-14 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答修飾因子の標的化送達のための組成物および方法 |
JP2008531590A (ja) | 2005-02-24 | 2008-08-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | カリウムイオンチャンネル開口薬としての新規なキノリン誘導体 |
JP2010523469A (ja) | 2007-03-30 | 2010-07-15 | ジェネンテック, インコーポレイテッド | 抗体及びイムノコンジュゲートとこれらの使用方法 |
JP6957154B2 (ja) | 2014-01-10 | 2021-11-02 | バーディー バイオファーマシューティカルズ インコーポレイテッド | 免疫療法のための化合物及び組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7290332B2 (ja) | 免疫療法のための化合物及び組成物 | |
US20220033503A1 (en) | Anti PD-L1 Conjugates for Treating Tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200417 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201224 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210316 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210615 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210812 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210825 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220104 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220401 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220603 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220704 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221004 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230203 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20230203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230207 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230227 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20230228 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230425 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230525 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7290332 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |